Protective Effects of Flavonoids Against Mitochondriopathies and Associated Pathologies: Focus on the Predictive Approach and Personalized Prevention.

1. Introduction

The terms mitochondrial function and dysfunction are widely employed in bioenergetics and cell biology. Abnormalities in mitochondrial processes, including adenosine triphosphate (ATP) generation, apoptosis, cytoplasmic and mitochondrial matrix calcium regulation, reactive oxygen species (ROS) generation and detoxification, metabolite synthesis, and the intracellular transport, can be termed as mitochondrial dysfunction [ 1 ]. Mitochondrial dysfunction affects various organs and tissues, including the brain, muscle, retina, cochlea, liver, and kidney, which are most susceptible to oxidative phosphorylation (OXPHOS) defects. Patients with mitochondrial disorders (mitochondriopathies) exhibit various symptoms, including deafness, visual impairment, heart, liver, and kidney problems, stroke, migraines, diabetes, epilepsy, ataxia, delayed motor and mental development, and failure to thrive, all of which are frequently observed in several non-mitochondrial disorders [ 2 ]. Therefore, the effective management of mitochondriopathies is a major challenge in medicine.

Currently, mitochondrial disorders are diagnosed based on functional studies, clinical, biochemical, and histopathologic examinations, and molecular genetic testing [ 3 ]. However, diagnostic techniques utilizing cell-free nucleic acids or biofluids such as blood, urine, saliva, cerebrospinal fluid, sweat, or tears could replace invasive tissue biopsies [ 4 , 5 , 6 , 7 ]. The paradigm shift from reactive to predictive, preventive, and personalized medicine (3PM) is based on healthcare approaches leveraging targeted preventive measures that account for chronic diseases and ethical as well as economic aspects of medical services [ 8 , 9 ]. 3PM also involves individualized patient profiling, which is important for patient stratification, characterization of individual predisposition, and personalized treatments [ 10 ]. Moreover, multi-level diagnostic approaches include molecular biological characterization, novel eHealth-based diagnostic tools, questionnaires, and medical imaging [ 9 ].

In recent years, the beneficial health effects of flavonoids, naturally occurring polyphenolic compounds, have attracted medical research, including their utilization in pathologies associated with mitochondrial impairments [ 11 ] such as cancers, cardiovascular and neurodegenerative diseases [ 12 ]. The efficacy of flavonoids is supported by extensive preclinical evidence that represents the basis for further research into the potential future use of these compounds in specific targeted and personalized therapy of mitochondriopathies according to the 3PM approach [ 13 , 14 , 15 , 16 , 17 , 18 , 19 ].

This review discusses the efficacy of flavonoids in mitochondriopathies such as cancer, cardiovascular diseases (CVDs), and neurodegenerative disorders, highlighting the need for advanced implementation of 3PM.

2. Mitochondrial Damage and Associated Impairments

In eukaryotic organisms, mitochondria have an essential role in cellular functions such as energy metabolism, biosynthesis, ionic regulation, oxidation and/or reduction, and signaling pathways associated with cell communication, aging, immune responses, apoptosis, survival, and death [ 12 ]. The principal functions of mitochondria are ATP synthesis through OXPHOS, metabolite oxidation by the Krebs cycle, and fatty acid β-oxidation [ 20 ]. The mitochondrial genome encodes key electron transport chain (ETC) proteins that play an essential role in energy production in aerobic organisms [ 21 ]. Human mitochondrial DNA (mtDNA) is a double-stranded circular molecule consisting of 16,569 base pairs [ 22 ]. Under normal conditions, mitochondria contain multiple copies (100 to 10,000 per cell) of their DNA [ 23 ].

The ETC is also a source of ROS and reactive nitrogen species (RNS), byproducts of OXPHOS that cause DNA, RNA, and protein damage [ 24 ]. The inability of base excision repair (BER) to repair the damaged mtDNA leads to ETC disruption associated with ROS production (shown in Figure 1 ). Further, the activity of ETC can also act as a predictor and target of drug (venetoclax) sensitivity in multiple myeloma patients [ 25 ]. Moreover, oxidative stress and insufficient DNA damage repair could increase DNA damage resulting in mitochondrial dysfunction in patients with depression. Therefore, a marker 8-oxoguanine of oxidative DNA damage obtained from fluid biopsies (blood, urine) could be beneficial for the prevention and prediction of neurodegenerative disorders as mitochondriopathies [ 26 ]. Subsequently, extensive oxidative mtDNA damage manifests in several mitochondrial dysfunctions and diseases [ 27 ]. Mitochondrial dysfunctions can also be caused by mtDNA mutations, deletions, and impaired DNA replication (shown in Figure 1 ) [ 28 ]. For example, the mtDNA m.3243A>G mutation can lead to clinical phenotypes related to two clinical syndromes: maternally inherited diabetes and deafness (MIDD), and mitochondrial encephalomyopathy, lactic acidosis, and strokelike episode (MELAS) syndrome [ 29 ]. Moreover, some clinical features of mitochondrial syndromes associated with mtDNA mutations include a maternal family history due to the maternal pattern of mitochondrial inheritance. The simplicity of analysis of mitochondrial genome sequencing due to the availability of consensus human sequence could help to recognize mtDNA disorders in terms of heredity. Other mtDNA mutations associated with mitochondrial dysfunction are acquired during life by the aging process. These acquired mtDNA mutations are often connected to age-related diseases such as diabetes. Therefore, the progress in the understanding of basic mitochondrial genetics is considered an important tool for analysis of the relationship between inherited mitochondrial mutations and disease phenotypes through the identification of acquired mtDNA mutations [ 30 , 31 ]. Moreover, mitochondrial dysfunction can be caused by pathogenic variants in nuclear genes associated with mtDNA maintenance, including those encoding mtDNA replication enzymes, proteins that function in the maintenance of the mitochondrial nucleotide pool, and proteins that participate in mitochondrial fusion (shown in Figure 1 ) [ 32 ]. Besides, the aging process is connected to a decrease in mitochondrial biogenesis (fusion and fission) and also in a critical process eliminating dysfunctional mitochondria characterized as mitophagy [ 20 ]. Moreover, the incidence and frequency of mtDNA mutations increase markedly with age, contributing to cellular senescence [ 33 ].

As discussed above, mitochondrial impairments are associated with various highly heterogeneous diseases in terms of their different clinical features and genetic etiology. Therefore, the analysis and/or elucidation of molecular mechanisms associated with mitochondrial impairments can represent the challenges for diagnosis and further clinical management [ 34 ]. Finally, mitochondrial dysfunction is a hallmark of many diseases known as mitochondriopathies, including malignancies, CVDs, and neurodegeneration. Therefore, it is imperative to find novel therapies targeting mitochondrial disease mechanisms.

2.1. Mitochondiopaties Are Involved in Cancer Development

Mitochondria have essential functions in apoptotic pathways and the mechanisms of the Warburg phenotype, processes that are closely related to cancer. Mitochondria play an essential role in the intrinsic pathway of apoptotic cell death associated with mitochondrial outer membrane permeabilization, cytochrome c release, apoptosome formation, caspase activation, and cell death [ 35 ]. Apoptosis evasion is a hallmark of human cancer development. Cancer cells leverage several survival strategies, including the activation of anti-apoptotic and pro-survival signaling through the inhibition of mitochondrial apoptosis. Therefore, intrinsic (mitochondrial) apoptotic pathways represent a promising target of anticancer strategies [ 36 ].

In 1956, Otto Warburg described the process by which cancer cells sustain rapid proliferation; this process, known as the Warburg effect, is characterized by increased glucose uptake and lactate secretion (aerobic glycolysis) even under normoxic conditions, suggesting that defects in mitochondrial respiration can promote tumorigenesis [ 37 , 38 ]. In mammals, modulation of protein kinases (PK), such as PKL, PKR, PKM1, and PKM2, augments the Warburg effect in cancer cells [ 39 ]. Moreover, mtDNA depletion leads to alterations in mitochondrial function in breast, renal, prostate, and other cancers, and age-related diseases, underscores the role of mitochondria in tumorigenesis [ 40 , 41 , 42 , 43 ]. Furthermore, various mutations in Krebs cycle enzymes, including succinate dehydrogenase (SDH), fumarate hydratase (FH), and isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2), are described in cancer cells [ 44 ]. SDH mutations are associated with hypoxia pathway activation, which can alter mitochondrial fusion and fission, mitophagy, and OXPHOS. In addition, FH and IDH mutations lead to tumor initiation through the repression of cellular differentiation, and IDH1 and IDH2 mutations cause an energy shift in cancer cells [ 45 , 46 ]. Abnormalities in the mentioned Krebs cycle enzymes promote carcinogenesis through the production of onco-metabolites, including 2-hydroxyglutarate and citrate, increased fatty acid β-oxidation, and epithelial-mesenchymal transition (EMT) induction [ 47 ].

Moreover, mutations in mtDNA, especially in genes for complexes I, III, IV, and V, which are closely associated with OXPHOS and redox regulation, were observed in endometrial, cervical, breast, and epithelial ovarian cancer cells [ 44 , 46 , 48 ]. Specifically, mutations in complex I are associated with a higher α-ketoglutarate/succinate ratio, which promotes tumorigenesis through hypoxia-inducible factor 1α (HIF1α) destabilization [ 49 ]. Although mutations in mtDNA lead to mitochondrial dysfunction and the potential for cancer development, these mutations also affect nuclear gene expression through retrograde signaling [ 44 ].

2.2. Mitochondrial Dysfunction in Cardiovascular Diseases

CVDs are the leading cause of global mortality and morbidity [ 50 ]. Mitochondria have a pivotal role in the homeostasis of the heart. Mitochondrial morphology is responsive to changes in cardiomyocytes [ 51 ]. Mitochondrial diseases that preferentially affect the heart are associated with mitochondrial dysfunctions, such as disruptions in OXPHOS or the ETC [ 52 ]. Structural and functional alterations in mitochondrial organelles cause ischemic cardiomyopathy, heart failure, and stroke [ 53 ].

Furthermore, disruptions in mitochondrial dynamics, including mitochondrial fusion, fission, biogenesis, and mitophagy, lead to the development and progression of CVDs such as diabetic cardiomyopathy, atherosclerosis, damage from ischemia-reperfusion, cardiac hypertrophy, and decompensated heart failure [ 54 ]. Several nuclear genes regulating mtDNA maintenance and replication, including mitochondrial transcription factor A (TFAM), mtDNA polymerase γ ( POLG ), and PEO1 (Twinkle), are altered in CVDs [ 55 ]. Besides, mtDNA mutations that dysregulate mtDNA gene expression promote the pathogenesis of stroke and myocardial infarction [ 56 ]. Moreover, hypoxia causes changes in cellular mechanisms that lead to oxidative stress and subsequent mitochondrial dysfunction [ 57 ].

In patients with atherosclerosis and associated CVDs dysfunctional mitochondria affect cellular respiration and energy production and also act as dangerous ROS generators leading to induction of apoptosis [ 58 ]. The accumulation of ROS and RNS in the heart by dysfunctional mitochondria is associated with several CVDs, including cardiomyopathies and heart failure [ 59 , 60 ]. Interestingly, ROS production caused by TFAM dysfunction is related to mtDNA damage and consequent cardiomyocyte cell cycle arrest resulting in lethal cardiomyopathy [ 61 ]. Moreover, the prognosis of cardiomyopathy is poor in children with mitochondrial diseases, especially those with mtDNA defects, including the m.3243A>G mutation in mitochondrially encoded tRNA-Leu (UUA/G) 1 ( MT-TL1 ), the m.13513G>A mutation in mitochondrially encoded NADH:Ubiquinone oxidoreductase core subunit 5 ( MT-ND5 ), the m.8528T>C mutation in the overlapping region of mitochondrially encoded ATP synthase membrane subunits 6 ( MT-ATP 6) and 8 ( MT-ATP8 ), the m.3302A>G mutation in MT-ND1 , the m.1644G>A mutation in mitochondrially encoded tRNA valine ( MT-TV ), and pathogenic mutations in BolA family member 3 ( BOLA3 ) and tafazzin TAZ. Children with mentioned mitochondrial mutations have a higher risk of cardiomyopathy and associated mortality. Therefore, the genetic analysis with detailed phenotyping of mitochondrial impairments could be useful for the prognosis of cardiomyopathy [ 62 ]. Moreover, several nuclear gene mutations can directly affect the mitochondrial respiratory chain and its components. The alterations in genes of complex I ( NDUFS1 , NDUFS2 , NDUFS3 ), complex IV ( SURF1 , SCO1 , SCO2 , COX10 , COX15 ), complex V ( ATP12 , TMEM70 ), mitochondrial translation ( TACO1 , EFG1 ), and cardiolipin biosynthesis ( TAZ1 ) are associated with cardiomyopathy [ 59 ]. Furthermore, intermyofibrillar mitochondria represent a well-organized network of long and dense organelles and contractile myofilaments. In heart failure, a disturbance in the physical and chemical interactions between intermyofibrillar mitochondria and sarcoplasmic reticula reduces cardiomyocyte contractility and induces cell death [ 63 ]. Moreover, heart failure can be characterized by mitochondrial calcium overload, higher ROS release, and reduced ATP production [ 64 ]. During heart failure, calcium overload commonly increases mitochondrial fission and dysfunction. Subsequently, these processes lead to a decrease in the activity of the heart that is characterized by a reduced ability to fill the left ventricle and eject blood to match the body’s demands. This metabolic demand of the heart could be associated with alterations in heart rate, myocardial inotropic state, and myocardial wall tension that in conclusion promote heart injury. The calcium accumulation is also associated with a reduction in mitochondrial energetics (ATP production) that leads to negative changes in ETC and OXPHOS associated with the generation of cell-damaging ROS and apoptosis induction [ 65 ]. Furthermore, cardiolipin is a key mitochondrial phospholipid in the inner mitochondrial membrane required for the activity of the ETC. The loss of cardiolipin causes ROS production associated with the disruption of cardiolipin peroxidation and cytochrome c release leading to cardiomyocyte apoptosis. In heart failure, this vicious cycle leads to mitochondrial dysfunction and subsequent cardiomyocyte death [ 66 ].

2.3. Mitochondriopathies in the Neurodegeneration

Normal mitochondrial dynamics are important for maintaining polarity in highly polarized neurons [ 67 , 68 ]. Neuronal cell death in brain disorders (neurodegeneration) and injury (neurotoxicity and ischemia) is connected to various changes in mitochondrial homeostasis and/or function that include traffic, quality control, turnover, bioenergetics, electron transport, and signaling [ 69 ]. Neurons depend more on OXPHOS to fulfill their energy demands than other cell types [ 70 ]. Neurodegenerative disorders are also characterized by the gradual accumulation of mtDNA mutations that can potentially decrease ETC and ATP production efficiency and increase ROS production [ 71 ]. A higher ROS level could cause further mtDNA mutations in a “vicious circle” that leads to cell death [ 72 ]. Moreover, abnormalities of the microtubule-associated protein tau (Tau) were observed in various neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and Pick’s disease [ 73 ]. Mitochondrial dysfunction is closely associated with tau pathology in AD; overexpression of hyperphosphorylated and aggregated tau is suggested to damage axonal transport and cause the abnormal distribution of mitochondria [ 74 ].

Mitochondrial dysfunction and oxidative stress contribute to AD and PD, the two most common age-related neurodegenerative diseases [ 71 ]. AD, a form of senile dementia, is characterized by the accumulation of damaged mitochondria during aging. Extracellular deposition of amyloid β-peptide (Aβ) plaques and the intracellular formation of neurofibrillary tangles (NFTs) occur in the cerebral cortex of AD patients [ 75 ]. In AD, oligomers of Aβ with hyperphosphorylated pTau cause the loss of synaptic function and cognitive impairment [ 76 , 77 ]. Several mutations are closely associated with mitochondrial function, including those in the genes encoding β-amyloid precursor protein (APP), presenilin 1 ( PSEN1) and 2 ( PSEN2), and apolipoprotein E (APOE4), lead to AD development. Various missense or deletion mutations of mitochondrial APP cause the inherited form of AD [ 73 ]. In addition to APP mutations, mutations in PSEN1 and PSEN2 are observed in early-onset familial AD [ 78 ]. Moreover, the contribution of APOE4 to AD pathogenesis is related to APOE4-mediated alterations of Aβ aggregation and clearance. APOE4 mutations constitute one of the major genetic risk factors for late-onset sporadic AD [ 79 ].

Furthermore, the pathological hallmarks of PD include the loss of dopaminergic neurons in the substantia nigra and the presence of misfolded α-synuclein (α-syn) in intra-cytoplasmic inclusions known as Lewy bodies [ 80 ]. PD arises from various mitochondrial dysfunctions, including bioenergetic and transcriptional defects, and alterations in dynamics (fusion or fission), size, morphology, trafficking, transport, and movement. Undoubtedly, mutations in mtDNA, nuclear DNA, and mitochondrial proteins are well described in PD [ 81 ]. Therefore, mutations or disturbances in E3 ubiquitin ligase ( Parkin) , α-syn, a parkin-associated protein involved with oxidative stress ( DJ1), ubiquitin carboxy-terminal hydrolase L1 ( UCHL1 ), auxilin ( DNAJC6 ), putative serine-threonine kinase ( PINK1 ), synaptojanin 1 ( SYNJ1 ), serine peptidase 2 ( HTRA2) , and endophilin A1 ( SH3GL2 ) disrupt several mitochondrial functions and may cause PD development [ 12 ].

3. Flavonoids Classification and Functions

Flavonoids represent an important class of natural substances. All flavonoids are synthesized in plants as bioactive secondary metabolites and contain a basic flavan skeleton that consists of a 15-carbon phenylpropanoid chain (C6-C3-C6 system) with a characteristic polyphenolic structure consisting of two phenyl rings and a heterocyclic pyran ring [ 82 , 83 ]. Flavonoids can be divided into six major groups: isoflavonoids, flavanones, flavanols, flavonols, flavones, and anthocyanidins [ 84 ]. Additional minor classes of flavonoids include chalcones, dihydrochalcones, and aurones are categorized into minor flavonoids [ 85 , 86 ]. Moreover, flavonoids are abundant in plant-based foods and are thus consumed through fruits, vegetables, nuts, seeds, grains, bark, roots, stems, flowers, tea, and wine [ 84 ]. The general chemical structures [ 83 ] and key representatives of the six major flavonoid classes [ 87 , 88 ] are presented in Figure 2 .

Flavonoids have many beneficial properties, such as antioxidant, free radical scavenging, hepatoprotective, cardioprotective, anti-inflammatory, immunomodulatory, antiangiogenic, antiviral, anticancer activities, and antidepressant-like effects [ 82 , 89 , 90 , 91 ]. Various flavonoids (vitexin, and baicalin) and other phytochemical compounds such ascurcumin (diarylheptanoid), lycopene (carotene), and ginsenoside (triterpenes), have neuroprotective effects against ischemic-induced injury [ 92 ]. Moreover, flavonoids can modulate several key mitochondrial enzymatic pathways [ 93 ]. Redox potentials associated with flavonoids’ chemical structure allow these compounds to thermodynamically scavenge ROS, including hydroxyl, superoxide, alkoxyl, alkyl-peroxyl, and nitric oxide radicals [ 94 ]. On the other hand, the oxidized reactive byproducts of the redox and scavenging mechanisms of flavonoids chemically destabilize these compounds [ 95 ]. Notably, the redox properties of flavonoids vary with the cellular conditions, dosage, treatment time, experimental model, tumorigenic state, and other factors. Under specific cellular conditions such as the occurrence of environmental factors or stressors, the antioxidants can act also as prooxidants. The proxidant activity of flavonoids, e.g., luteolin and fisetin, can be characterized by the ability to undergo autoxidation catalyzed by the transition metals to produce superoxide anions [ 96 , 97 ]. For the determination of prooxidant status is important to evaluate various reductant-oxidant markers such as glutathione (GSH) to GSSG, NADPH to NAPD−, and NADH to NAD− [ 98 ]. Prooxidant properties of flavonoids can cause oxidative damage through reactions with different biomolecules, such as lipids, proteins, and DNA [ 99 , 100 ].

Flavonoids generally exhibit low oral bioavailability due to their poor aqueous solubility. The composition of their sources can also affect their bioavailability. Therefore, the gut microbiome is crucial for the absorption and metabolism of flavonoids [ 101 ]. Anthocyanidins and pro-anthocyanidins have the lowest bioavailability, while quercetin glucosides, catechin, flavanones, isoflavones, and gallic acid have the highest one [ 102 ]. This is the issue that has to be considered from a biotechnological point of view for increasing their bioavailability and facilitating clinical implementation.

Flavonoids provide a valuable contribution in the framework of 3PM. The role of 3PM is to introduce predictive analytical approaches by cost-effective targeted prevention and personalization of medical services. Predispositions and early diagnostics, targeting high-risk individuals, individualized patient profiling, and patient stratification could significantly improve the therapeutic strategies of various diseases [ 12 ]. Despite the above-mentioned limitations, flavonoids represent environmentally friendly and cost-effective substances with minimal side effects during long-term administration. Health beneficial effects of flavonoids are promising for 3PM concepts including predictive approaches, targeted prevention, and personalization of medical services, that can positively influence preventive and therapeutic strategies, e.g., anti-cancer effects of flavonoids that can inhibit the initiation of metastasis and their spread in high-risk individuals [ 86 ].

4. Protective Effects of Flavonoids against Pathologies Associated with Mitochondriopathies

Regular consumption of flavonoids exerts beneficial health effects that can potentially be utilized against several mitochondriopathies, including cancers, CVDs such as atherosclerosis, and neurodegenerative disorders such as AD [ 103 , 104 ].

4.1. Preclinical Research

Various in vitro and in vivo studies evaluated the efficacy of flavonoids in mitochondria-associated impairments and/or diseases.

4.1.1. Cancer

Preclinical cancer research demonstrated the potent capacity of flavonoids to modulate pro-carcinogenic mitochondrial dysfunction, especially in signaling cascades associated with the Warburg phenotype and the intrinsic apoptotic pathway. Apigenin (4′,5,7-trihydroxyflavone) blocked cellular glycolysis by inhibiting tumor-specific PKM2 activity and expression in HCT116, HT29, and DLD1 colon cancer cells. Moreover, apigenin treatment decreased the PKM2/PKM1 ratio by blocking the β-catenin/c-Myc/PTBP1 signaling pathway [ 105 ]. Furthermore, quercetin suppresses glycolysis by downregulating PKM2, glucose transporter 1 (GLUT1), and lactate dehydrogenase A (LDHA) in MCF-7 and MDA-MB-231 human breast cancer cell lines. Additionally, quercetin treatment inhibited glycolysis and induced autophagy by inhibiting p-Akt/Akt in murine MCF-7 xenografts [ 106 ]. Moreover, shikonin treatment inhibited glucose uptake, lactate production, and ATP production in Lewis lung carcinoma and B16 melanoma cells by decreasing PKM2 activity and consequently reversing the Warburg effect [ 107 ]. Furthermore, the enzyme hexokinase 2 (HK2) converts glucose to glucose-6-phosphate in the first step of glucose metabolism [ 108 ] and promotes the Warburg effect in cancer cells [ 109 ]. However, xanthohumol downregulated HK2 and glycolysis and subsequently increased cytochrome c release to activate the intrinsic (mitochondrial) apoptotic pathway in the HT29, SW480, LOVO, HCT116, and SW620 colorectal cancer cell lines [ 13 ]. The apoptosis-inducing factor (AIF), a mitochondrial protein, is implicated in caspase-independent programmed cell death following its translocation to the nucleus [ 110 ]. In an in vitro investigation using multiple biochemical assays, xanthohumol was detected to cause proliferation inhibition and death of the rat glioma C6 cells (in a time- and dose-dependent manner) via a mechanism of inducing AIF pathway apoptosis by triggering mitochondrial stress [ 111 ]. Impressively, pyruvate dehydrogenase kinase 1 (PDK1) is a gatekeeper of glycolysis and mitochondrial OXPHOS; its inhibition can reverse the Warburg phenotype of tumor cells [ 112 ]. Licochalcone A suppressed HIF1α, GLUT1, and PDK1 in HCT116 colorectal cancer, H1299 non-small cell lung carcinoma, and H322 primary bronchioalveolar carcinoma cells. Besides, higher intracellular oxygen content resulting from the direct inhibition of mitochondrial respiration was observed after licochalcone A treatment [ 113 ]. Furthermore, EGCG promoted mitochondrial depolarization and suppressed glycolysis in 4T1 murine breast cancer cells, as demonstrated through reduced levels of glucose, lactate, ATP, HIF-1α, and GLUT1. EGCG also inhibited several glycolytic enzymes, including HK, phosphofructokinase, LDH, and PK, in the same model [ 14 ]. Moreover, albanol B, a benzofuran flavonoid, exerted potent anti-cancer effects by inducing apoptosis through mtROS production and associated increased phosphorylation of Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) in A549, BZR, H1975, and H226 human lung cancer cell lines. The anti-cancer potential of albanol B was associated with the induction of apoptosis and G 2 /M phase cell cycle arrest through mtROS production [ 114 ]. Lysionotin, a bioactive flavonoid from Lysionotus pauciflorus Maxim., has been shown in a combined in vitro (HepG2 and SMMC-7721 cells) and in vivo (HepG2 and SMMC-7721-xenograft tumor mouse model) experiment the ability to exert remarked anti-liver cancer properties through a mechanism that causes caspase-3 mediated mitochondrial apoptosis pathway. The outcomes of this study have also revealed that lysionotin could control oxidative stress, which was found to be involved in lysionotin-mediated mitochondrial apoptosis by regulating nuclear factor erythroid 2–related factor 2 (Nrf2) signaling pathway [ 115 ]. BAS-4, a prenylated flavonoid (isolated from the Amazon plant Brosimum acutifolium ), was observed to cause anticancer properties against the C6 glioma cells by promoting apoptosis mediated by mitochondrial transmembrane potential loss and Akt pathway disruption [ 116 ]. Furthermore, treatment with isoquercitrin (25 µM), a bioactive flavonol, exhibited anti-cancer effects against SK-Mel-2 human melanoma cells, and the mechanism was observed to be related to its effect on mitochondria-mediated apoptosis. Various mechanisms were reported, including the reduction in the levels of procaspase-8 and -9, and Bcl-2 protein, and the enhancement of cleaved PARP and Bax expressions. The caspase-independent mitochondrial-mediated apoptosis was found to be linked to the increase of AIF and Endo G protein expressions. Besides, the anti-proliferative activity was determined to be associated with the downregulation of the PI3K/Akt/mTOR signaling pathway [ 117 ]. In a mechanistic study using in vitro (A549 cells) and in silico assays, the flavonoid myricetin (73 µg/mL) showed the capacity to induce anticancer properties against lung cancer cells by promoting cell cycle arrest and ROS-reliant mitochondria-facilitated apoptosis [ 118 ]. Moreover, the flavonoid silibinin, a bioactive substance from Silybum marianum , exerted a cytotoxic effect against SCC-25 human oral squamous carcinoma cells. The in vitro assay disclosed the mechanism of action via inducing apoptosis by releasing mitochondrial cytochrome c into the cytosol following by activating caspases-3 and -9 [ 119 ].

As demonstrated in the above-discussed preclinical studies, flavonoids have the potential to reverse the Warburg effect by targeting signaling molecules associated with mitochondrial respiratory defects. Moreover, the anti-Warburg effect of flavonoids could be multiplied by an antioxidant, anti-inflammatory, ROS scavenging, immunomodulatory, anti-angiogenic [ 82 ], and other anti-cancer activities such the participation in cell cycle arrest, apoptosis induction, autophagy, and suppression of cancer cell proliferation and invasiveness [ 83 ].

4.1.2. Cardiovascular Diseases

Flavonoids potently affect the complex pathways associated with CVD-related mitochondrial dysfunctions. Nuclear factor-κB (NF-κB), a transcription factor, regulates many cellular processes, including immunity, inflammation, and cell survival. Besides, NF-κB signaling is also essential for mitochondrial processes, such as biogenesis, metabolism, and apoptosis [ 120 ]. Further, NF-κB is a redox-sensitive transcription factor because ROS can regulate its activity. An extract of Aronia melanocarpa rich in polyphenols, especially anthocyanins, activated NF-κB by ROS production in human aortic endothelial cells (HAECs), resulting in potential cardioprotection [ 121 ]. Moreover, the peroxisome proliferation-activated receptor (PPAR) family regulates mitochondrial function, turnover, and energy metabolism. Therefore, PPAR activity can represent a therapeutic target to restore impaired mitochondrial function [ 122 ]. Cornelian cherry ( Cornus mas L.) fruits rich in anthocyanins, phenolic acid, flavonols, and iridoids decreased serum triglyceride levels and increased PPARα protein expression in the liver, suggesting protective effects on diet-induced hypertriglyceridemia and atherosclerosis in a hypercholesterolemic rabbit model. Moreover, increased expression of PPAR in the liver indicated its hypolipidemic effect obtained from enhanced fatty acid catabolism which subsequently led to decreased triglyceride levels [ 123 ].

Interestingly, mitochondrial dysfunction contributes to myocardial ischemia-reperfusion-induced cardiomyocyte apoptosis. Yu et al. recently reported that naringenin can alleviate myocardial ischemia-reperfusion injury by reducing mitochondrial oxidative stress damage, cytochrome c release, and oxidative markers. Moreover, mitochondrial biogenesis was maintained by increased nuclear respiratory factor 1 (NRF1), TFAM, and OXPHOS II, III, and IV subunit complexes in vitro (H9c2 cardiomyoblasts) and in vivo (rats) models [ 15 ]. Moreover, mitochondrial dysfunction has a crucial role in the pathogenesis of fructose-induced cardiac hypertrophy. The bioflavonoid naringin inhibited mtROS production and thereby relieved mitochondrial dysfunction in H9c2 rat myoblasts after fructose exposure and high fructose-induced cardiac hypertrophy. Indeed, the suppression of cardiomyocyte hypertrophy by naringin was mediated through downregulation of the AMP-activated protein kinase (AMPK)-mechanistic target of rapamycin (mTOR) signaling axis [ 124 ].

Furthermore, proteins involved in mitochondrial dynamics, including mitofusin 2 (Mfn2), mitochondrial dynamin-like GTPase (OPA1), dynamin-related protein 1 (Drp1), and fission 1 (Fis-1), regulate mitochondrial homeostasis under stress conditions [ 125 ]. Treatment of myocardial ischemic mice with 7,8-dihydroxyflavone (7,8-DHF) reversed cardiac dysfunction and cardiomyocyte abnormalities through the suppression of mitochondrial fission, as demonstrated by decreased protein levels of Fis-1. Besides, 7,8-DHF improved the mitochondrial membrane potential and reduced mitochondrial superoxide levels in hydrogen peroxide (H 2 O 2 )-treated H9c2 rat myoblasts. 7,8-DHF also prevents mitochondrial fission by inhibiting proteolytic cleavage of OPA1 in H9c2 cells [ 126 ]. Similarly, 7,8-DHF improved cardiac function and inhibited cardiac injury mediated by increased OPA1 protein expression, Akt activation, OXPHOS, and mitochondrial membrane potential dysregulation in doxorubicin-induced cardiotoxicity in Kunming mice and H9c2 cells [ 127 ].

In many cases, diabetic cardiomyopathy causes heart failure. Dihydromyricetin increased mitochondrial function in streptozotocin-induced diabetic mice, as demonstrated by increases in ATP content, citrate synthase activity, and complex Ι, ΙΙ, ΙΙΙ, ΙV, and V activities [ 128 ]. Moreover, quercetin protected mitochondria by restoring the cellular redox balance after isoproterenol-induced cardiac hypertrophy in mice. Quercetin attenuated cardiac hypertrophy by increasing sulfhydryl group availability and mitochondrial superoxide dismutase activity and reducing mitochondrial permeability transition pore opening in the same model [ 129 ]. Impressively, intraperitoneal injection of luteolin in mice with lipopolysaccharide-induced myocardial injury mitigated mitochondrial injury and oxidative stress by decreasing AMPK phosphorylation in septic heart tissue and stabilizing the mitochondrial membrane potential. In summary, luteolin attenuates lipopolysaccharide-induced myocardial injury associated with mitochondrial impairments in mice through the inhibition of apoptosis and enhancing autophagy via modulation of AMPK signaling [ 16 ]. Furthermore, icariin, a prenylated flavonol glycoside, protected H9C2 cardiomyocytes from oxidative stress by scavenging ROS and promoting ERK pathway phosphorylation. Icariin also preserved Ca 2+ homeostasis and mitochondrial membrane potential stability [ 130 ]. Moreover, cyanidin, an anthocyanin pigment, improved mitochondrial function in mice with lipopolysaccharide-induced myocardial injury by reducing oxidative damage through the associated factor Opa1 and the antioxidant gene thioredoxin-1 (Trx1) [ 131 ]. Tilianin, a natural flavonoid glycoside, is known for its cardioprotective effect against myocardial ischemia/reperfusion injury (MIRI). In a comprehensive preclinical study, the mechanism of action of this compound has been determined through hindering Ca 2+ /calmodulin-dependent protein kinase II (CaMKII)-mediated mitochondrial apoptosis and c-Jun N -terminal kinase (JNK)/NF-κB inflammation [ 132 ]. Moreover, the cardioprotective effect of fisetin, a natural flavonoid, has been comprehensively investigated in a combined experiment ( in vitro , in vivo , and in silico ). The results showed that treatment with fisetin could suppress mitochondrial oxidative stress and mitochondrial dysfunction and repress glycogen synthase kinase 3β (GSK3β) activity, where the induced effects were reported as possible mechanisms of action [ 133 ]. In another animal study, the administration of fisetin (20 mg/kg) attenuated the myocardial infarct size, apoptosis, lactate dehydrogenase, and creatine kinase in serum/perfusate of the rat hearts subjected to ischemia/reperfusion injury. The results concluded that phosphoinositide 3-kinase (PI3K) activation is needed to mediate fisetin-associated cardioprotection against ischemia/reperfusion injury in rat heart [ 134 ]. Furthermore, phosphorylation of Drp1 at serine 616 is associated with increased Drp1 enzyme activities that consequently contribute to cell death. It is known that myocardial injury after cardiac arrest (CA) leads to critical myocardial dysfunction and death, including mitochondrial dysfunction. In this regard, baicalin, a natural flavonoid molecule, was studied in vivo for its cardioprotection against CA-induced injury by regulating mitochondrial dysfunction. Male Sprague-Dawley rats were treated with baicalin (100 mg/kg, administered intragastrically once daily for 4 weeks) and the results proved that this compound has potently reduced mitochondrial dysfunction and exhibited cardioprotective effect after CA by a mechanism via inhibiting the phosphorylation at serine 616 and translocation of Drp1 and excessive fission of mitochondria. In conclusion, the inhibition of Drp1-mediated mitochondrial fission might be the possible mechanism of baicalin in preventing CA-induced myocardial injury [ 135 ].

Several preclinical ( in vitro and in vivo ) studies indicate that flavonoids can reverse CVD-associated mitochondriopathies by targeting various molecules and signaling pathways.

4.1.3. Neurodegenerative Disorders

Aluminum, a neurotoxicant, causes oxidative damage as observed in various neurodegenerative disorders such as AD [ 136 ]. However, naringin reduced the neurotoxic effects of aluminum in rats. The administration of a higher dose of naringin (80 mg/kg) significantly improved cognitive performance, reduced mitochondrial oxidative damage, and downregulated certain mitochondrial enzymes, including NADH dehydrogenase, succinate dehydrogenase, and cytochrome oxidase, compared to control aluminum-treated rats [ 137 ]. APP and Aβ co-localize in mitochondria; Aβ inhibits the respiratory chain, and altered mitochondrial function can result in changes in APP and eventual alterations in the production of amyloidogenic derivatives [ 138 ]. Nevertheless, quercetin reduced Aβ and BACE1-mediated cleavage of APP in a murine triple transgenic AD model (3xTg-AD) [ 139 ]. Treatment with quercetin also decreased ROS levels and restored normal mitochondrial morphology in hippocampal neurons affected by H 2 O 2 -induced neuronal toxicity and Aβ-induced neurodegeneration this suggests that quercetin could prevent neuronal mitochondrial dysfunction [ 140 ].

Furthermore, quercetin upregulated protein kinase D1 (PKD1), Akt, cAMP response-element binding protein (CREB), and the CREB target gene BDNF— all of which are associated with mitochondrial dysfunction related to neurodegenerative disorders [ 141 , 142 ]—in murine MN9D dopaminergic cells. Besides, quercetin increased the mitochondrial bioenergetic capacity and protected MN9D cells against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity [ 143 ]. Interestingly, acetylcholinesterase activity causes mitochondrial impairments; however, cholinesterase inhibitors increase mitochondrial biogenesis through AMP-Activated PK in the hippocampus [ 144 ]. Mitochondrial γ-secretase participates in the metabolism of mitochondria-associated APP [ 145 ]. In this regard, a meta-analysis of 17 preclinical studies on AD animal models revealed that EGCG exerts neuroprotective effects by reducing acetylcholinesterase activity, enhancing α-, β-, and γ-secretase activity, decreasing Aβ 42 levels and tau phosphorylation, and modulating anti-oxidative, anti-inflammatory, and anti-apoptotic processes [ 146 ]. Moreover, the flavonoid isoquercitrin enhanced mitochondrial function by attenuating mitochondrial membrane potential loss, downregulating the outer mitochondrial membrane voltage-dependent anion channel (VDAC), and preventing mtROS accumulation in a model of streptozotocin-induced AD in murine Neuro-2a neuroblastoma cells [ 18 ]. Two other flavonoids, mangiferin, and morin, alleviated A β -induced mitochondrial impairments such as decreased respiratory capacity, mitochondrial membrane depolarization, and cytochrome c release in cortical neurons in the AD model [ 147 ].

Quercetin increased mitochondrial complex I activity (demonstrated by increased NADH oxidation), constraining mtROS production in a rotenone-induced rat model of PD [ 17 ]. Recently, the neuroprotective effect of quercetin has been investigated in 6-OHDA-treated PC12 rat pheochromocytoma cells and the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD. The outcomes of in vitro assay showed that treatment with quercetin (20 μM) promoted mitochondrial quality control, diminished oxidative stress, boosted the levels of the mitophagy markers ( Parkin and PINK1 ), and lowered α-syn protein expression in 6-OHDA-treated PC12 cells. Moreover, the results of in vivo test proved that treatment of PD rats with quercetin (10 mg/kg/day and 30 mg/kg/day) for two weeks by oral gavage has led to producing progressive PD-like motor behaviors, alleviate neuronal death, and lessen mitochondrial damage and α-syn accumulation. All experimental results assumed that the neuroprotective effect of quercetin was defeated by the knockdown of both PINK1 and Parkin [ 148 ]. Furthermore, in PC12 rat adrenal gland cells, the naturally occurring hydroxy flavonoid myricitrin ameliorated 6-OHDA–induced mitochondrial damage through the inhibition of mitochondrial oxidation, as demonstrated by reduced ROS production and lipid peroxidation in rat brain mitochondria [ 149 ]. Myricitrin also mitigated mitochondrial dysfunction by increasing DJ-1 activity in SN4741 substantia nigra dopaminergic cells with 1-methyl-4-phenylpyridinium-induced mitochondrial dysfunction [ 150 ]. Another study revealed that hesperidin, a citrus flavanol, exerted antioxidative and antiapoptotic properties by maintaining mitochondrial function against rotenone-induced apoptosis in an SK-N-SH neuroblastoma cellular model of PD [ 151 ].

The mechanism of the neuroprotective effect of tilianin against cerebral ischemia using oxygen-glucose deprivation (OGD) protocol was detailed, where tilianin was found to affect mitochondrial function and inflammation by alleviating CaMKII-dependent mitochondrion-mediated apoptosis and MAPK/NF-κB inflammatory activation following cellular OGD injury [ 152 ]. In traditional Chinese medicine, hydroxysafflor yellow A (HSYA; a C-glucosyl quinochalcone that belongs to the flavonoid family) has been widely employed as a protective agent against ischemia/reperfusion injury. This compound has also been noticed to reduce the levels of ROS and suppress cellular apoptosis. In a mechanistic study, HSYA was found to decrease phenylalanine levels and promote mitochondrial function via the upregulation of mitochondrial fission protein Drp1, leading to causing a neuroprotective effect against cerebral ischemia/reperfusion injury [ 153 ]. A recent in vivo study using male Sprague Dawley rats was designed to assess the protective effects of HSYA-mediated mitochondrial permeability transition pore (mPTP) on cerebral ischemia/reperfusion injury and its mechanism. The obtained results indicated that HSYA treatment remarkably enhanced brain microvascular endothelial cells (BMECs) viability, lowered the production of ROS, the opening of mPTP, and translocation of cytochrome c . HSYA was also detected to potentiate MEK and boost phosphorylation of ERK expression in BMECs, hinder apoptosis mediated by mitochondrial, and repress cyclophilin D (CypD). Interestingly, HSYA has been found to decrease the infarct size in animal models [ 154 ]. Nobiletin, a polymethoxylated flavonoid, is commonly detected in the genus Citrus . In a multiple biochemical investigation, nobiletin was found to regulate mitochondrial dysfunction mediated by the ETC system downregulation by hindering complex I and III in pure mitochondria and the cortical neurons of rats. This molecule at various concentrations in micromolar ranges was noticed to potently reduce mitochondrial ROS production, restrain apoptotic signaling, improve ATP production, and improve neuronal viability under conditions of complex I repression. The induced effect was related to the downregulation of translocation of AIF, and the upregulation of complex I activity, and the expression of antioxidant factors such as Nrf2 and heme oxygenase 1 (HO-1). Based on the acquired data, this study suggested that nobiletin might have promising neuroprotective action against neurodegenerative diseases such as AD and PD [ 155 ].

As discussed above, flavonoids can alleviate mitochondrial impairments mainly by reducing ROS or maintaining mitochondrial functions; these abilities can improve cognitive function associated with the two most common neurodegenerative disorders, AD and PD ( Table 1 ).

4.2. Clinical Data

In addition to preclinical studies, clinical research also highlights the efficacy of flavonoids in the etiopathology of mitochondriopathies, including cancers, CVDs, and neurodegenerative disorders.

4.2.1. Cancer

Despite the beneficial effects of flavonoids elucidated in preclinical cancer studies, no clinical studies to date have directly focused on the mechanistic effects of flavonoids on mitochondrial impairments. Otto Warburg hypothesized that mitochondrial dysfunction initiates cancer formation characterized by decreased glycolytic energy production in contrast with mitochondrial respiration [ 156 ]. Targeted therapies using flavonoids against the Warburg effect could have important applications in future cancer management [ 157 ]. Flavonoid supplements could support cancer prevention, especially at high-risk individuals; key risk factors include obesity (due to low physical activity and/or sedentary lifestyle) [ 158 , 159 ], stress exposure [ 160 ], Flammer syndrome [ 161 ], accelerated aging processes [ 162 ], and chronic inflammation [ 163 ]. Moreover, genetic predispositions [ 164 ], the early detection of mitochondrial impairments [ 156 ], and the detection of cancer with metastatic potential [ 165 ] are highly predictive in cancer management. Therefore, individualized patient profiling is an essential tool for cancer predisposition and early diagnostics [ 166 ]. In evaluating the applications of flavonoids in patient stratification and individualized therapy, it is essential to consider the varying mechanisms underlying cancer, as cancers associated with mitochondrial impairments may differ from those associated with nuclear mutations [ 167 , 168 , 169 ].

Eventually, the application of plant-derived natural substances such as flavonoids alone or in combination with anticancer drugs could constitute a promising strategy against the Warburg phenotype within the 3PM framework.

4.2.2. Cardiovascular Diseases

Mitochondria play a significant role in the pathogenesis of various CVDs. However, current clinical research aimed at finding novel molecules applicable against CVDs focuses primarily on the general protective properties of flavonoids rather than their direct impact on mitochondrial impairments.

Isoflavone treatment for 12 weeks reduced serum high-sensitivity (hs)-C-reactive protein (CRP) levels and improved brachial flow-mediated dilatation in patients with clinically manifested atherosclerosis and prior ischemic stroke [ 170 ]. Moreover, dietary intake of flavonoid-rich foods can prevent mitochondriopathies related to CVDs. Flavonoids, including flavonols, flavones, flavanones, anthocyanidins, and proanthocyanidins, significantly decreased the risk of CVD mortality [ 171 ]. Interestingly, flavonoids in black, green, herbal, and berry teas possess protective effects against various CVDs, including stroke, myocardial infarction, and coronary heart diseases [ 172 ].

Moreover, transthyretin amyloidosis is a rare progressive systemic disease characterized by increased left ventricular wall thickness and diastolic dysfunction. In many cases, this disease leads to amyloidotic transthyretin mitochondrial cardiomyopathy [ 173 ]. After 12 months of treatment with green tea and its extracts, in which EGCG is abundant, echocardiography revealed no changes in cardiac wall thickness and mass progression, suggesting that green tea exerts protective effects against amyloidotic transthyretin mitochondrial cardiomyopathy [ 174 ]. Furthermore, menopause in women is often related to the aging process and higher CVD risk with possible mitochondrial connections [ 175 , 176 ]. In women with early menopause, supplementation with soy protein and isoflavones significantly decreased various CVD risk markers [ 177 ].

Moreover, altered mitochondrial functions also cause hyperinsulinemia, glucose intolerance, dyslipidemia, obesity, and elevated blood pressure, collectively known as metabolic syndrome [ 178 ]. Blueberries rich in flavonoids decreased plasma oxidized low-density lipoprotein (LDL), serum malondialdehyde, and hydroxynonenal concentrations in patients with metabolic syndrome. These results suggest that blueberries have cardioprotective effects and alleviate metabolic syndrome [ 179 ]. Furthermore, cranberries ( Vaccinium macrocarpon Ait.) rich in polyphenols, including flavonoids and ellagic acid, increased plasma antioxidant capacity and reduced lipid oxidation by decreasing oxidized LDL and malondialdehyde in women with metabolic syndrome [ 180 ].

Furthermore, mitochondrial structure and/or function alterations are associated with a higher risk of various CVDs, including ischemic cardiomyopathy, heart failure, and stroke [ 53 ]. Therefore, higher intake of fruit-based flavonoids, especially through anthocyanin-rich (cyanidin, delphinidin, malvidin, pelargonidin, petunidin, peonidin) and flavanone-rich (eriodictyol, hesperetin, naringenin) foods, reduced the risk of nonfatal myocardial infarction and ischemic stroke in men [ 181 ]. Flavonoids also have potential in the secondary prevention of ischemic heart disease. Flavonoids in chokeberry ( Aronia melanocarpa ) extract reduced serum 8-isoprostane, oxidized LDL, hsCRP, and monocyte chemoattractant protein-1 (MCP-1) levels and increased adiponectin levels in patients who survived myocardial infarction and had received statin therapy [ 182 ]. In conclusion, current clinical studies provide predominantly general data on the efficacy of flavonoids against CVDs rather than precise mechanisms related to mitochondrial function.

4.2.3. Neurodegenerative Disorders

Neurodegenerative disorders are closely associated with mitochondrial deregulation [ 69 ]. Flavonoids can potently attenuate the negative impact of mitochondrial dysfunction on the pathogenesis of neurodegenerative disorders, as shown by preclinical research. However, current clinical studies primarily offer results dealing with the general effects of flavonoids on neurodegenerative diseases.

Increased cellular oxidative stress leads to α-syn accumulation and subsequently to mitochondrial dysfunction [ 183 ]. The flavonoid EGCG inhibits α-syn aggregation and reduces associated toxicity. Therefore, EGCG treatment can potentially delay or prevent various mitochondriopathies associated with neurodegenerative disorders [ 184 ]. However, EGCG treatment did not modify the progression of multiple system atrophy, a neurodegenerative disease associated with α-syn aggregation in neurons and oligodendrocytes. In addition, higher doses (1200 mg) were connected to hepatotoxic effects in several patients [ 185 ].

Moreover, mitochondrial dysfunction is associated with impaired homocysteine metabolism, which leads to aging tissue degeneration [ 186 ]. Therefore, elevated plasma homocysteine levels are typical in AD patients in a moderate phase compared to AD patients in the initial and control groups. A polyphenol-rich antioxidant drink decreased plasma total homocysteine levels in AD patients, especially in the moderate phase [ 187 ]. The flavonoid-rich Ginkgo biloba extract (EGb 761 ® ) improved cognition, daily living, and social behavior in patients with uncomplicated AD or multi-infarct dementia—which are both associated with mitochondrial impairments [ 188 ]. Furthermore, the administration of EGCG in patients delayed the progression of multiple system atrophy-associated disabilities [ 189 ].

Although beneficial effects of flavonoids were observed in the mentioned clinical studies, detailed mechanisms concerning mitochondrial impairments were not evaluated. Therefore, current clinical research indicates significant positive effects of flavonoids on neurodegenerative diseases, but the direct effects of flavonoids on mitochondrial function remain unclarified. Table 2 provides a detailed overview of the discussed clinical studies on the role of flavonoids in the etiopathology of mitochondriopathies, including cancer, CVDs, and neurodegenerative disorders.

Although the beneficial effects of flavonoids reinforce the hypothesis that the consumption of these naturally occurring compounds could be responsible for health benefits, the evidence from the clinical sphere is still limited and there are doubts about their use in practice. Different results of the efficacy of flavonoids in clinical studies could be based on different patient profiling (age, gender, race, or financial status) e.g., in the meta-analysis of Peters et al. (2001) [ 172 ] or a small number of participants in studies of Kristen et al. (2012) [ 174 ]. The use of flavonoids could be also associated with various side effects. A study by Levin et al. (2019) described the hepatotoxic effects after treatment with a higher dose of EGCG (1200 mg) in several patients [ 185 ]. Therefore, the determination of accurate doses of flavonoids for patients could mitigate the side effects and increase their safety. Moreover, the limitations of several studies are connected to the insufficient investigation of more precise molecular mechanisms of the efficacy of flavonoids. Nevertheless, as demonstrated in our previous studies [ 12 , 72 ] biomarkers obtained from liquid biopsy could facilitate the prediction and diagnosis of mitochondrial impairments. Further, liquid biopsy could replace the invasive tissue biopsies associated with various health risks. Despite some limitations, flavonoids still represent environmentally friendly and cost-effective substances suitable for long-term use, and more precise evaluations of the effects of flavonoids, along with individualized patient profiling and patient stratification, could improve medical strategies for the prevention and treatment of mitochondriopathies.

Figure 3 summarizes the efficacy and potential of flavonoids in preventing or treating various mitochondriopathies related to cancer, CVDs, and neurodegenerative disorders based on preclinical and clinical findings.

5. Conclusions

Recent progress in 3P medicine demonstrates that patient stratification and individualized patient profiling are instrumental for cost-effective targeted prevention and treatments tailored to the person [ 4 , 5 , 7 , 9 ]. Individualized evaluation of the mitochondrial impairments [ 190 , 191 ] is essential for the risk assessment related to mitochondriopathies and associated pathologies, including but not restricted to cancer, CVDs, and neurodegenerative disorders [ 192 , 193 , 194 ]. Targeting mitochondrial homeostasis is a promising innovation in the overall therapeutic strategy.

The treatment and prevention of diseases in patients with mitochondriopathies have attracted a lot of attention in current research, novel therapeutic strategies. Contextually, flavonoids, naturally occurring polyphenolic compounds are of particular interest exerting significant health benefits in primary, secondary, and tertiary care protecting against stress overload, genotoxicity, mitochondrial dysfunction, and associated pathologies [ 195 , 196 , 197 , 198 , 199 ].

Both preclinical and clinical studies demonstrate flavonoids as highly protective agents reducing mitochondrial impairments and mitigating risks of associated pathologies. To improve individual outcomes and to increase cost-efficacy, the 3PM approach is strongly recommended to implement these benefits in healthcare providing new opportunities for prevention and treatment of stress-related disorders, oncology, cardiology, and neurology, amongst others [ 4 , 5 , 7 , 9 , 200 , 201 ].

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author Contributions

O.G. was responsible for the paper concepts and 3 PM-related content. The manuscript was drafted by L.K., K.Z., M.Š. (Miroslava Šudomová), O.B. and P.K., and critically revised by O.G., D.B., L.S., F.A.G., S.T.S.H., M.A., R.K.A.-I. and K.B. The tables were created by A.L. Figures were prepared by L.K. and M.S. (Marek Samec), while P.K. and M.P. provided skilled assistance and supervised the overall preparation of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

Open Access funding enabled and organized by Project DEAL. This publication was created thanks to the support under the Operational Program Integrated Infrastructure for the project: Integrative strategy in the development of personalized medicine for selected malignant tumors and its impact on quality of life, IMTS: 313011V446, co-financed by the European Regional Development Fund and by the LISPER project (grant Nr. 313011V446) in a bilateral agreement with the European Association for Predictive, Preventive and Personalised Medicine. D. B. was supported by a National Priorities Research Program grant (NPRP 11S-1214-170101, June 2019-Current) from the Qatar National Research Fund (QNRF, a member of Qatar Foundation).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Natarajan V. Chawla R. Mah T. Vivekanandan R. Tan S.Y. Sato P.Y. Mallilankaraman K. Mitochondrial Dysfunction in Age-Related Metabolic Disorders Proteom. 2020 20 e1800404 10.1002/pmic.201800404 PMC12087358 32131138

2. Calvo S. Jain M. Xie X. A Sheth S. Chang B. A Goldberger O. Spinazzola A. Zeviani M. A Carr S. Mootha V.K. Systematic identification of human mitochondrial disease genes through integrative genomics Nat. Genet. 2006 38 576 582 10.1038/ng1776 16582907

3. Molnar M.J. Kovacs G.G. Mitochondrial diseases Hum. Hypothal. Neuropsychiatr. Disord. 2018 145 147 155 10.1016/b978-0-12-802395-2.00010-9 28987165

4. Golubnitschaja O. Topolcan O. Kucera R. Costigliola V. Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine–EPMA World Congress Supplement 2020 EPMA J. 2020 11 1 133 10.1007/s13167-020-00206-1 32837665 PMC7435254

5. Crigna A.T. Samec M. Koklesova L. Liskova A. Giordano F.A. Kubatka P. Golubnitschaja O. Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope? EPMA J. 2020 11 603 627 10.1007/s13167-020-00226-x PMC7594983 33144898

6. Stastny I. Zubor P. Kajo K. Kubatka P. Golubnitschaja O. Dankova Z. Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer Clin. Breast Cancer 2020 20 e711 e722 10.1016/j.clbc.2020.05.009 32792225

7. Gerner C. Costigliola V. Golubnitschaja O. Multiomic patterns in body fluids: Technological challenge with a great potential to implement the advanced paradigm of 3P medicine Mass Spectrom. Rev. 2020 39 442 451 10.1002/mas.21612 31737933

8. Sica D.A. Drug Absorption in the Management of Congestive Heart Failure: Loop Diuretics Congest. Hear. Fail. 2003 9 287 292 10.1111/j.1527-5299.2003.02399.x 14564148

9. Barrett M. Boyne J. Brandts J. Rocca H.-P.B.-L. De Maesschalck L. De Wit K. Dixon L. Eurlings C. Fitzsimons D. Golubnitschaja O. Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care EPMA J. 2019 10 445 464 10.1007/s13167-019-00188-9 31832118 PMC6882991

10. Golubnitschaja O. Costigliola V. Common origin but individual outcomes: time for new guidelines in personalized healthcare Pers. Med. 2010 7 561 568 10.2217/pme.10.42 29776246

11. El-Hattab A.W. Zarante A.M. Almannai M. Scaglia F. Therapies for mitochondrial diseases and current clinical trials Mol. Genet. Metab. 2017 122 1 9 10.1016/j.ymgme.2017.09.009 PMC5773113 28943110

12. Koklesova L. Samec M. Liskova A. Zhai K. Büsselberg D. Giordano F.A. Kubatka P. Golunitschaja O. Mitochondrial impairments in aetiopathology of multifactorial diseases: common origin but individual outcomes in context of 3P medicine EPMA J. 2021 12 27 40 10.1007/s13167-021-00237-2 PMC7931170 33686350

13. Liu W. Li W. Liu H. Yu X. Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis Int. J. Biol. Sci. 2019 15 2497 2508 10.7150/ijbs.37481 31595166 PMC6775317

14. Wei R. Mao L. Xu P. Zheng X. Hackman R.M. Mackenzie G.G. Wang Y. Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models Food Funct. 2018 9 5682 5696 10.1039/C8FO01397G 30310905 PMC7480214

15. Yu L.-M. Dong X. Xue X.-D. Zhang J. Li Z. Wu H.-J. Yang Z.-L. Yang Y. Wang H.-S. Naringenin improves mitochondrial function and reduces cardiac damage following ischemia-reperfusion injury: the role of the AMPK-SIRT3 signaling pathway Food Funct. 2019 10 2752 2765 10.1039/C9FO00001A 31041965

16. Wu B. Song H. Fan M. You F. Zhang L. Luo J. Li J. Wang L. Li C. Yuan M. Luteolin attenuates sepsis-induced myocardial injury by enhancing autophagy in mice Int. J. Mol. Med. 2020 45 1477 1487 10.3892/ijmm.2020.4536 32323750 PMC7138288

17. Karuppagounder S. Madathil S. Pandey M. Haobam R. Rajamma U. Mohanakumar K. Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson’s disease in rats Neuroscience 2013 236 136 148 10.1016/j.neuroscience.2013.01.032 23357119

18. Chen L. Feng P. Peng A. Qiu X. Lai W. Zhang L. Protective effects of isoquercitrin on streptozotocin-induced neurotoxicity J. Cell. Mol. Med. 2020 24 10458 10467 10.1111/jcmm.15658 32738031 PMC7521287

19. Ashrafizadeh M. Bakhoda M.R. Bahmanpour Z. Ilkhani K. Zarrabi A. Makvandi P. Khan H. Mazaheri S. Darvish M. Mirzaei H. Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer Front. Chem. 2020 8 829 10.3389/fchem.2020.00829 33195038 PMC7593821

20. Chistiakov D.A. Sobenin I. Revin V.V. Orekhov A.N. Bobryshev Y.V. Mitochondrial Aging and Age-Related Dysfunction of Mitochondria BioMed Res. Int. 2014 2014 1 7 10.1155/2014/238463 24818134 PMC4003832

21. John J.C.S. Srirattana K. Tsai T.-S. Sun X. The mitochondrial genome: how it drives fertility Reprod. Fertil. Dev. 2018 30 118 139 10.1071/RD17408 29539308

22. Anderson S. Bankier A.T. Barrell B.G. De Bruijn M.H.L. Coulson A.R. Drouin J. Eperon I.C. Nierlich D.P. Roe B.A. Sanger F. Sequence and organization of the human mitochondrial genome Nature 1981 290 457 465 10.1038/290457a0 7219534

23. Srinivasan S. Guha M. Kashina A. Avadhani N.G. Mitochondrial dysfunction and mitochondrial dynamics-The cancer connection Biochim. Biophys. Acta (BBA) Bioenerg. 2017 1858 602 614 10.1016/j.bbabio.2017.01.004 PMC5487289 28104365

24. Mandavilli B.S. Santos J.H. Van Houten B. Mitochondrial DNA repair and aging Mutat. Res. Mol. Mech. Mutagen. 2002 509 127 151 10.1016/S0027-5107(02)00220-8 12427535

25. Bajpai R. Sharma A. Achreja A. Edgar C.L. Wei C. Siddiqa A.A. Gupta V.A. Matulis S.M. McBrayer S.K. Mittal A. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma Nat. Commun. 2020 11 1 16 10.1038/s41467-020-15051-z 32144272 PMC7060223

26. Czarny P. Wigner P. Galecki P. Sliwinski T. The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 2018 80 309 321 10.1016/j.pnpbp.2017.06.036 28669580

27. Prakash A. Doublie S. Base Excision Repair in the Mitochondria J. Cell. Biochem. 2015 116 1490 1499 10.1002/jcb.25103 25754732 PMC4546830

28. A Butow R. Avadhani N.G. Mitochondrial Signaling: The Retrograde Response Mol. Cell 2004 14 1 15 10.1016/S1097-2765(04)00179-0 15068799

29. Picard M. Hirano M. Disentangling (Epi)Genetic and Environmental Contributions to the Mitochondrial 3243A>G Mutation Phenotype JAMA Neurol. 2016 73 923 925 10.1001/jamaneurol.2016.1676 27322764 PMC8515924

30. Taylor R.W. Turnbull D.M. Mitochondrial DNA mutations in human disease Nat. Rev. Genet. 2005 6 389 402 10.1038/nrg1606 15861210 PMC1762815

31. Andrews R.M. Kubacka I. Chinnery P.F. Lightowlers R.N. Turnbull D.M. Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA Nat. Genet. 1999 23 147 10.1038/13779 10508508

32. El-Hattab A.W. Craigen W.J. Scaglia F. Mitochondrial DNA maintenance defects Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2017 1863 1539 1555 10.1016/j.bbadis.2017.02.017 28215579

33. Wei Y.-H. Wu S.-B. Ma Y.-S. Lee H.-C. Respiratory function decline and DNA mutation in mitochondria, oxidative stress and altered gene expression during aging Chang. Gung Med. J. 2009 32 113 132 19403001

34. Boggan R. Lim A. Taylor R.W. McFarland R. Pickett S.J. Resolving complexity in mitochondrial disease: Towards precision medicine Mol. Genet. Metab. 2019 128 19 29 10.1016/j.ymgme.2019.09.003 31648942

35. Lopez J. Tait S.W.G. Mitochondrial apoptosis: killing cancer using the enemy within Br. J. Cancer 2015 112 957 962 10.1038/bjc.2015.85 25742467 PMC4366906

36. Pfeffer C.M. Singh A.T.K. Apoptosis: A Target for Anticancer Therapy Int. J. Mol. Sci. 2018 19 448 10.3390/ijms19020448 29393886 PMC5855670

37. Warburg O. On respiratory impairment in cancer cells Science 1956 124 269 270 13351639

38. Potter M. Newport E. Morten K.J. The Warburg effect: 80 years on Biochem. Soc. Trans. 2016 44 1499 1505 10.1042/BST20160094 27911732 PMC5095922

39. Yang K.M. Kim K. Protein kinase CK2 modulation of pyruvate kinase M isoforms augments the Warburg effect in cancer cells J. Cell. Biochem. 2018 119 8501 8510 10.1002/jcb.27078 30015359

40. Tseng L.-M. Yin P.-H. Chi C.-W. Hsu C.-Y. Wu C.-W. Lee L.-M. Wei Y.-H. Lee H.-C. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer Genes Chromosom. Cancer 2006 45 629 638 10.1002/gcc.20326 16568452

41. Horton T.M. Petros J.A. Heddi A. Shoffner J. Kaufman A.E. Graham S.D. Gramlich T. Wallace D.C. Novel mitochondrial DNA deletion found in a renal cell carcinoma Genes Chromosom. Cancer 1996 15 95 101 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z 8834172

42. Petros J.A. Baumann A.K. Ruiz-Pesini E. Amin M.B. Sun C.Q. Hall J. Lim S. Issa M.M. Flanders W.D. Hosseini S.H. mtDNA mutations increase tumorigenicity in prostate cancer Proc. Natl. Acad. Sci. USA 2005 102 719 724 10.1073/pnas.0408894102 15647368 PMC545582

43. Kujoth G.C. Hiona A. Pugh T.D. Someya S. Panzer K. Wohlgemuth S.E. Hofer T. Seo A.Y. Sullivan R. Jobling W.A. Mitochondrial DNA Mutations, Oxidative Stress, and Apoptosis in Mammalian Aging Science 2005 309 481 484 10.1126/science.1112125 16020738

44. Wallace D.C. Mitochondria and cancer Nat. Rev. Cancer 2012 12 685 698 10.1038/nrc3365 23001348 PMC4371788

45. Raimundo N. Baysal B.E. Shadel G.S. Revisiting the TCA cycle: signaling to tumor formation Trends Mol. Med. 2011 17 641 649 10.1016/j.molmed.2011.06.001 21764377 PMC3205302

46. Pustylnikov S. Costabile F. Beghi S. Facciabene A. Targeting mitochondria in cancer: current concepts and immunotherapy approaches Transl. Res. 2018 202 35 51 10.1016/j.trsl.2018.07.013 30144423 PMC6456045

47. Sajnani K. Islam F. Smith R.A. Gopalan V. Lam A.K.-Y. Genetic alterations in Krebs cycle and its impact on cancer pathogenesis Biochimie 2017 135 164 172 10.1016/j.biochi.2017.02.008 28219702

48. Farhood B. Ashrafizadeh M. Khodamoradi E. Hoseini-Ghahfarokhi M. Afrashi S. Musa A.E. Najafi M. Targeting of cellular redox metabolism for mitigation of radiation injury Life Sci. 2020 250 117570 10.1016/j.lfs.2020.117570 32205088

49. Gasparre G. Porcelli A.M. Lenaz G. Romeo G. Relevance of Mitochondrial Genetics and Metabolism in Cancer Development Cold Spring Harb. Perspect. Biol. 2013 5 a011411 10.1101/cshperspect.a011411 23378588 PMC3552507

50. Maaliki D. A Shaito A. Pintus G. El-Yazbi A. Eid A.H. Flavonoids in hypertension: a brief review of the underlying mechanisms Curr. Opin. Pharmacol. 2019 45 57 65 10.1016/j.coph.2019.04.014 31102958

51. Hoppel C.L. Tandler B. Fujioka H. Riva A. Dynamic organization of mitochondria in human heart and in myocardial disease Int. J. Biochem. Cell Biol. 2009 41 1949 1956 10.1016/j.biocel.2009.05.004 19446651 PMC3221317

52. Lee S.R. Han J. Mitochondrial Mutations in Cardiac Disorders Adv. Exp. Med. Biol. 2017 982 81 111 10.1007/978-3-319-55330-6_5 28551783

53. Pecoraro M. Pinto A. Popolo A. Mitochondria and Cardiovascular Disease: A Brief Account Crit. Rev. Eukaryot. Gene Expr. 2019 29 295 304 10.1615/CritRevEukaryotGeneExpr.2019028579 31679291

54. Vásquez-Trincado C. García-Carvajal I. Pennanen C. Parra V. Hill J.A. Rothermel B.A. Lavandero S. Mitochondrial dynamics, mitophagy and cardiovascular disease J. Physiol. 2016 594 509 525 10.1113/JP271301 26537557 PMC5341713

55. Tyynismaa H. Suomalainen-Wartiovaara A. Mouse models of mitochondrial DNA defects and their relevance for human disease EMBO Rep. 2009 10 137 143 10.1038/embor.2008.242 19148224 PMC2637315

56. Umbria M. Ramos A. Aluja M.P. Santos C. The role of control region mitochondrial DNA mutations in cardiovascular disease: stroke and myocardial infarction Sci. Rep. 2020 10 1 10 10.1038/s41598-020-59631-x 32066781 PMC7026394

57. Jin H.-J. Li C.G. Tanshinone IIA and Cryptotanshinone Prevent Mitochondrial Dysfunction in Hypoxia-Induced H9c2 Cells: Association to Mitochondrial ROS, Intracellular Nitric Oxide, and Calcium Levels Evid. Based Complement. Altern. Med. 2013 2013 1 11 10.1155/2013/610694 PMC3603679 23533503

58. Kattoor A.J. Pothineni N.V.K. Palagiri D. Mehta J.L. Oxidative Stress in Atherosclerosis Curr. Atheroscler. Rep. 2017 19 42 10.1007/s11883-017-0678-6 28921056

59. Figueira T.R. Barros M. Camargo A.A. Castilho R.F. Ferreira J.C.B. Kowaltowski A.J. Sluse F.E. Souza-Pinto N. Vercesi A.E. Mitochondria as a Source of Reactive Oxygen and Nitrogen Species: From Molecular Mechanisms to Human Health Antioxidants Redox Signal. 2013 18 2029 2074 10.1089/ars.2012.4729 23244576

60. Seddon M. Looi Y.H. Shah A.M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure Heart 2007 93 903 907 10.1136/hrt.2005.068270 16670100 PMC1994416

61. Zhang D. Li Y. Heims-Waldron D. Bezzerides V. Guatimosim S. Guo Y. Gu F. Zhou P. Lin Z. Ma Q. Mitochondrial Cardiomyopathy Caused by Elevated Reactive Oxygen Species and Impaired Cardiomyocyte Proliferation Circ. Res. 2018 122 74 87 10.1161/CIRCRESAHA.117.311349 29021295 PMC5756124

62. Imai-Okazaki A. Kishita Y. Kohda M. Mizuno Y. Fushimi T. Matsunaga A. Yatsuka Y. Hirata T. Harashima H. Takeda A. Cardiomyopathy in children with mitochondrial disease: Prognosis and genetic background Int. J. Cardiol. 2019 279 115 121 10.1016/j.ijcard.2019.01.017 30642647

63. Kiyuna L.A. Albuquerque R. Chen C.-H. Mochly-Rosen D. Ferreira J.C.B. Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities Free. Radic. Biol. Med. 2018 129 155 168 10.1016/j.freeradbiomed.2018.09.019 30227272 PMC6309415

64. Santulli G. Xie W. Reiken S.R. Marks A.R. Mitochondrial calcium overload is a key determinant in heart failure Proc. Natl. Acad. Sci. USA 2015 112 11389 11394 10.1073/pnas.1513047112 26217001 PMC4568687

65. Palaniyandi S.S. Qi X. Yogalingam G. Ferreira J.C.B. Mochly-Rosen D. Regulation of mitochondrial processes: A target for heart failure Drug Discov. Today: Dis. Mech. 2010 7 e95 e102 10.1016/j.ddmec.2010.07.002 21278905 PMC3026286

66. Dolinsky V.W. Cole L.K. Sparagna G.C. Hatch G.M. Cardiac mitochondrial energy metabolism in heart failure: Role of cardiolipin and sirtuins Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids 2016 1861 1544 1554 10.1016/j.bbalip.2016.03.008 26972373

67. Hollenbeck P.J. Saxton W.M. The axonal transport of mitochondria J. Cell Sci. 2005 118 5411 5419 10.1242/jcs.02745 16306220 PMC1533994

68. Samarghandian S. Farkhondeh T. Pourbagher-Shahri A.M. Ashrafizadeh M. Folgado S.L. Rajabpour-Sanati A. Khazdair M.R. Green tea catechins inhibit microglial activation which prevents the development of neurological disorders Neural Regen. Res. 2020 15 1792 1798 10.4103/1673-5374.280300 32246619 PMC7513986

69. Chaturvedi R.K. Beal M.F. Mitochondrial Diseases of the Brain Free. Radic. Biol. Med. 2013 63 1 29 10.1016/j.freeradbiomed.2013.03.018 23567191

70. Rose J. Brian C. Woods J. Pappa A. Panayiotidis M.I. Powers R. Franco R. Mitochondrial dysfunction in glial cells: Implications for neuronal homeostasis and survival Toxicology 2017 391 109 115 10.1016/j.tox.2017.06.011 28655545 PMC5681369

71. Yan M.H. Wang X. Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease Free Radic. Biol. Med. 2013 62 90 101 10.1016/j.freeradbiomed.2012.11.014 23200807 PMC3744189

72. Liskova A. Samec M. Koklesova L. Kudela E. Kubatka P. Golubnitschaja O. Mitochondriopathies as a Clue to Systemic Disorders—Analytical Tools and Mitigating Measures in Context of Predictive, Preventive, and Personalized (3P) Medicine Int. J. Mol. Sci. 2021 22 2007 10.3390/ijms22042007 33670490 PMC7922866

73. Jeong S. Molecular and Cellular Basis of Neurodegeneration in Alzheimer’s Disease Mol. Cells 2017 40 613 620 10.14348/molcells.2017.0096 28927263 PMC5638769

74. Cheng Y. Bai F. The Association of Tau With Mitochondrial Dysfunction in Alzheimer’s Disease Front. Neurosci. 2018 12 163 10.3389/fnins.2018.00163 29623026 PMC5874499

75. Goedert M. Spillantini M.G. A Century of Alzheimer’s Disease Science 2006 314 777 781 10.1126/science.1132814 17082447

76. Kosik K.S. Joachim C.L. Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease Proc. Natl. Acad. Sci. USA 1986 83 4044 4048 10.1073/pnas.83.11.4044 2424016 PMC323662

77. Masters C.L. Simms G. Weinman N.A. Multhaup G. McDonald B.L. Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc. Natl. Acad. Sci. USA 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021 PMC397973

78. Tanzi R.E. The Genetics of Alzheimer Disease Cold Spring Harb. Perspect. Med. 2012 2 a006296 10.1101/cshperspect.a006296 23028126 PMC3475404

79. Bu G. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy Nat. Rev. Neurosci. 2009 10 333 344 10.1038/nrn2620 19339974 PMC2908393

80. Balestrino R. Schapira A.H. Parkinson disease Eur. J. Neurol. 2020 27 27 42 10.1111/ene.14108 31631455

81. Bose A. Beal M.F. Mitochondrial dysfunction in Parkinson’s disease J. Neurochem. 2016 139 216 231 10.1111/jnc.13731 27546335

82. Kumar S. Pandey A.K. Chemistry and Biological Activities of Flavonoids: An Overview Sci. World J. 2013 2013 1 16 10.1155/2013/162750 PMC3891543 24470791

83. Kopustinskiene D.M. Jakstas V. Savickas A. Bernatoniene J. Flavonoids as anticancer agents Nutrients 2020 12 457 10.3390/nu12020457 PMC7071196 32059369

84. Panche A.N. Diwan A.D. Chandra S.R. Flavonoids: an overview J. Nutr. Sci. 2016 5 e47 10.1017/jns.2016.41 28620474 PMC5465813

85. Ninomiya M. Koketsu M. Minor Flavonoids (Chalcones, Flavanones, Dihydrochalcones, and Aurones) Nat. Prod. 2013 1867 1900

86. Liskova A. Koklesova L. Samec M. Smejkal K. Samuel S.M. Varghese E. Abotaleb M. Biringer K. Kudela E. Danko J. Flavonoids in Cancer Metastasis Cancers 2020 12 1498 10.3390/cancers12061498 32521759 PMC7352928

87. Ciumărnean L. Milaciu M.V. Runcan O. Vesa S.C. Răchișan A.L. Negrean V. Perné M.-G. Donca V.I. Alexescu T.-G. Para I. The effects of favonoids in cardiovascular diseases Molecules 2020 25 4320 10.3390/molecules25184320 PMC7571023 32967119

88. Abotaleb M. Samuel S.M. Varghese E. Varghese S. Kubatka P. Líšková A. Büsselberg D. Flavonoids in Cancer and Apoptosis Cancers 2018 11 28 10.3390/cancers11010028 30597838 PMC6357032

89. Yahfoufi N. Alsadi N. Jambi M. Matar C. The Immunomodulatory and Anti-Inflammatory Role of Polyphenols Nutrients 2018 10 1618 10.3390/nu10111618 PMC6266803 30400131

90. Guan L.-P. Liu B.-Y. Antidepressant-like effects and mechanisms of flavonoids and related analogues Eur. J. Med. Chem. 2016 121 47 57 10.1016/j.ejmech.2016.05.026 27214511

91. Mirossay L. Varinská L. Mojžiš J. Antiangiogenic Effect of Flavonoids and Chalcones: An Update Int. J. Mol. Sci. 2017 19 27 10.3390/ijms19010027 PMC5795978 29271940

92. Manish P. Wei Ling L. Seong Lin T. Mohamad Fairuz Y. Flavonoids and its Neuroprotective Effects on Brain Ischemia and Neurodegenerative Diseases Curr. Drug Targets 2018 19 1710 1720 10.2174/1389450119666180326125252 29577854

93. Kozłowska A. Szostak-Wegierek D. Flavonoids--food sources and health benefits Rocz. Państw. Zakł. Hig. 2014 65 79 85 25272572

94. Prochazkova D. Boušová I. Wilhelmová N. Antioxidant and prooxidant properties of flavonoids Fitoterapia Elsevier Amsterdam, The Netherlands 2011 10.1016/j.fitote.2011.01.018 21277359

95. Airoldi C. La Ferla B. D’Orazio G. Ciaramelli C. Palmioli A. Flavonoids in the Treatment of Alzheimer’s and Other Neurodegenerative Diseases Curr. Med. Chem. 2018 25 3228 3246 10.2174/0929867325666180209132125 29424298

96. Lin Y. Shi R. Wang X. Shen H.-M. Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy Curr. Cancer Drug Targets 2008 8 634 646 10.2174/156800908786241050 18991571 PMC2615542

97. Constantin R.P. Constantin J. Pagadigorria C.L.S. Ishii-Iwamoto E.L. Bracht A. De Castro C.V. Yamamoto N.S. Prooxidant activity of fisetin: Effects on energy metabolism in the rat liver J. Biochem. Mol. Toxicol. 2010 25 117 126 10.1002/jbt.20367 20957679

98. Rahal A. Kumar A. Singh V. Yadav B. Tiwari R. Chakraborty S. Dhama K. Oxidative Stress, Prooxidants, and Antioxidants: The Interplay BioMed Res. Int. 2014 2014 1 19 10.1155/2014/761264 PMC3920909 24587990

99. Lee-Hilz Y.Y. Boerboom A.-M.J.F. Westphal A.H. Van Berkel W.J.H. Aarts J.M.M.J.G. Rietjens I.M.C.M. Pro-Oxidant Activity of Flavonoids Induces EpRE-Mediated Gene Expression Chem. Res. Toxicol. 2006 19 1499 1505 10.1021/tx060157q 17112238

100. Eren-Guzelgun B. Ince E. Gurer-Orhan H. In vitro antioxidant/prooxidant effects of combined use of flavonoids Nat. Prod. Res. 2017 32 1446 1450 10.1080/14786419.2017.1346637 28669231

101. Cassidy A. Minihane A.M. The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids Am. J. Clin. Nutr. 2017 105 10 22 10.3945/ajcn.116.136051 27881391 PMC5183723

102. Rodríguez-García C. Sánchez-Quesada C. Gaforio J.J. Dietary Flavonoids as Cancer Chemopreventive Agents: An Updated Review of Human Studies Antioxidants 2019 8 137 10.3390/antiox8050137 PMC6562590 31109072

103. Koes R. Verweij W. Quattrocchio F.M. Flavonoids: a colorful model for the regulation and evolution of biochemical pathways Trends Plant. Sci. 2005 10 236 242 10.1016/j.tplants.2005.03.002 15882656

104. Rees A. Dodd G.F. Spencer J.P.E. The Effects of Flavonoids on Cardiovascular Health: A Review of Human Intervention Trials and Implications for Cerebrovascular Function Nutrients 2018 10 1852 10.3390/nu10121852 PMC6315948 30513729

105. Shan S. Shi J. Yang P. Jia B. Wu H. Zhang X. Li Z. Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis J. Agric. Food Chem. 2017 65 8136 8144 10.1021/acs.jafc.7b02757 28829588

106. Jia L. Huang S. Yin X. Zan Y. Guo Y. Han L. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction Life Sci. 2018 208 123 130 10.1016/j.lfs.2018.07.027 30025823

107. Zhao X. Zhu Y. Hu J. Jiang L. Li L. Jia S. Zen K. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis Sci. Rep. 2018 8 1 8 10.1038/s41598-018-31615-y 30266938 PMC6162216

108. Siu M.K.Y. Jiang Y.-X. Wang J.-J. Leung T.H.Y. Han C.Y. Tsang B.K. Cheung A.N.Y. Ngan H.Y.S. Chan K.K.L. Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades Cancers 2019 11 813 10.3390/cancers11060813 PMC6627345 31212816

109. Pedersen P.L. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen J. Bioenerg. Biomembr. 2007 39 211 222 10.1007/s10863-007-9094-x 17879147

110. Luo Q. Wu X. Zhao P. Nan Y. Chang W. Zhu X. Su D. Liu Z. OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation Adv. Sci. 2021 8 2002874 10.1002/advs.202002874 PMC8061361 33898171

111. Hou S. Song Y. Sun D. Zhu S. Wang Z. Xanthohumol-Induced Rat Glioma C6 Cells Death by Triggering Mitochondrial Stress Int. J. Mol. Sci. 2021 22 4506 10.3390/ijms22094506 33925918 PMC8123451

112. Deng X. Wang Q. Cheng M. Chen Y. Yan X. Guo R. Sun L. Li Y. Liu Y. Pyruvate dehydrogenase kinase 1 interferes with glucose metabolism reprogramming and mitochondrial quality control to aggravate stress damage in cancer J. Cancer 2020 11 962 973 10.7150/jca.34330 31949499 PMC6959030

113. Park M.K. Ji J. Haam K. Han T.-H. Lim S. Kang M.-J. Lim S.S. Ban H.S. Licochalcone A inhibits hypoxia-inducible factor-1α accumulation by suppressing mitochondrial respiration in hypoxic cancer cells Biomed. Pharmacother. 2021 133 111082 10.1016/j.biopha.2020.111082 33378978

114. Phan T.N. Kim O. Ha M.T. Hwangbo C. Min B.-S. Lee J.-H. Albanol B from Mulberries Exerts Anti-Cancer Effect through Mitochondria ROS Production in Lung Cancer Cells and Suppresses In Vivo Tumor Growth Int. J. Mol. Sci. 2020 21 9502 10.3390/ijms21249502 33327489 PMC7764986

115. Yang A. Zhang P. Sun Z. Liu X. Zhang X. Liu X. Wang D. Meng Z. Lysionotin induces apoptosis of hepatocellular carcinoma cells via caspase-3 mediated mitochondrial pathway Chem. Interact. 2021 344 109500 10.1016/j.cbi.2021.109500 33989594

116. Maués L. Alves G. Couto N. Da Silva B. Arruda M. Macchi B. Sena C. Prado A. Crespo-Lopez M. Silva E. Flavonoids from the Amazon plant Brosimum acutifolium induce C6 glioma cell line apoptosis by disrupting mitochondrial membrane potential and reducing AKT phosphorylation Biomed. Pharmacother. 2019 113 108728 10.1016/j.biopha.2019.108728 30856536

117. Won Y.-S. Kim J.-H. Lizardo R.C.M. Min H.-J. Cho H.-D. Hong S.-M. Seo K.-I. The Flavonol Isoquercitrin Promotes Mitochondrial-Dependent Apoptosis in SK-Mel-2 Melanoma Cell via the PI3K/AKT/mTOR Pathway Nutrients 2020 12 3683 10.3390/nu12123683 PMC7760408 33260329

118. Rajendran P. Maheshwari U. Muthukrishnan A. Muthuswamy R. Anand K. Ravindran B. Dhanaraj P. Balamuralikrishnan B. Chang S.W. Chung W.J. Myricetin: versatile plant based flavonoid for cancer treatment by inducing cell cycle arrest and ROS–reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico prediction Mol. Cell. Biochem. 2021 476 57 68 10.1007/s11010-020-03885-6 32851589

119. Iyangar R.M. Devaraj E. Silibinin Triggers the Mitochondrial Pathway of Apoptosis in Human Oral Squamous Carcinoma Cells Asian Pac. J. Cancer Prev. 2020 21 1877 1882 10.31557/APJCP.2020.21.7.1877 32711410 PMC7573425

120. Ivanova I.G. Perkins N.D. Hypoxia induces rapid, STAT3 and ROS dependent, mitochondrial translocation of RelA(p65) and IκBα Biosci. Rep. 2019 39 10.1042/BSR20192101 PMC6746997 31484794

121. Zapolska-Downar D. Bryk D. Małecki M. Hajdukiewicz K. Sitkiewicz D. Aronia melanocarpa fruit extract exhibits anti-inflammatory activity in human aortic endothelial cells Eur. J. Nutr. 2012 51 563 572 10.1007/s00394-011-0240-1 21863241 PMC3397226

122. Corona J.C. Duchen M.R. PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease Free. Radic. Biol. Med. 2016 100 153 163 10.1016/j.freeradbiomed.2016.06.023 27352979 PMC5145801

123. Sozański T. Kucharska A. Szumny A. Magdalan J. Bielska K. Merwid-Ląd A. Woźniak-Biel A. Dzimira S. Piórecki N. Trocha M. The protective effect of the Cornus mas fruits (cornelian cherry) on hypertriglyceridemia and atherosclerosis through PPARα activation in hypercholesterolemic rabbits Phytomedicine 2014 21 1774 1784 10.1016/j.phymed.2014.09.005 25444446

124. Park J.H. Ku H.J. Kim J.K. Park J.-W. Lee J.H. Amelioration of High Fructose-Induced Cardiac Hypertrophy by Naringin Sci. Rep. 2018 8 1 11 10.1038/s41598-018-27788-1 29930336 PMC6013481

125. Zhang Y. Wang Y. Xu J. Tian F. Hu S. Chen Y. Fu Z. Melatonin attenuates myocardial ischemia-reperfusion injury via improving mitochondrial fusion/mitophagy and activating the AMPK-OPA1 signaling pathways J. Pineal Res. 2019 66 e12542 10.1111/jpi.12542 30516280

126. Wang Z. Wang S.-P. Shao Q. Li P.-F. Sun Y. Luo L.-Z. Yan X.-Q. Fan Z.-Y. Hu J. Zhao J. Brain-derived neurotrophic factor mimetic, 7,8-dihydroxyflavone, protects against myocardial ischemia by rebalancing optic atrophy 1 processing Free. Radic. Biol. Med. 2019 145 187 197 10.1016/j.freeradbiomed.2019.09.033 31574344

127. Zhao J. Du J. Pan Y. Chen T. Zhao L. Zhu Y. Chen Y. Zheng Y. Liu Y. Sun L. Activation of cardiac TrkB receptor by its small molecular agonist 7,8-dihydroxyflavone inhibits doxorubicin-induced cardiotoxicity via enhancing mitochondrial oxidative phosphorylation Free. Radic. Biol. Med. 2019 130 557 567 10.1016/j.freeradbiomed.2018.11.024 30472367

128. Wu B. Lin J. Luo J. Han D. Fan M. Guo T. Tao L. Yuan M. Yi F. Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice BioMed Res. Int. 2017 2017 1 13 10.1155/2017/3764370 PMC5379084 28421194

129. Alexandre J.V.D.L. Viana Y.I.P. David C.E.B. Cunha P.L.O. Albuquerque A.C. Varela A.L.N. Kowaltowski A.J. Facundo H.T. Quercetin treatment increases H2O2 removal by restoration of endogenous antioxidant activity and blocks isoproterenol-induced cardiac hypertrophy Naunyn-Schmiedeberg’s Arch. Pharmacol. 2021 394 217 226 10.1007/s00210-020-01953-8 32930861

130. Song Y.-H. Cai H. Zhao Z.-M. Chang W.-J. Gu N. Cao S.-P. Wu M.-L. Icariin attenuated oxidative stress induced-cardiac apoptosis by mitochondria protection and ERK activation Biomed. Pharmacother. 2016 83 1089 1094 10.1016/j.biopha.2016.08.016 27551754

131. Li F. Lang F. Wang Y. Zhai C. Zhang C. Zhang L. Hao E. Cyanidin ameliorates endotoxin-induced myocardial toxicity by modulating inflammation and oxidative stress through mitochondria and other factors Food Chem. Toxicol. 2018 120 104 111 10.1016/j.fct.2018.05.053 29803697

132. Jiang H. Xing J. Fang J. Wang L. Wang Y. Zeng L. Li Z. Liu R. Tilianin Protects against Ischemia/Reperfusion-Induced Myocardial Injury through the Inhibition of the Ca2+/Calmodulin-Dependent Protein Kinase II-Dependent Apoptotic and Inflammatory Signaling Pathways BioMed Res. Int. 2020 2020 1 18 10.1155/2020/5939715 33102583 PMC7568786

133. Shanmugam K. Ravindran S. Kurian G.A. Rajesh M. Fisetin Confers Cardioprotection against Myocardial Ischemia Reperfusion Injury by Suppressing Mitochondrial Oxidative Stress and Mitochondrial Dysfunction and Inhibiting Glycogen Synthase Kinase 3β Activity Oxidative Med. Cell. Longev. 2018 2018 1 16 10.1155/2018/9173436 PMC5845518 29636855

134. Shanmugam K. Boovarahan S.R. Prem P. Sivakumar B. A Kurian G. Fisetin Attenuates Myocardial Ischemia-Reperfusion Injury by Activating the Reperfusion Injury Salvage Kinase (RISK) Signaling Pathway Front. Pharmacol. 2021 12 566470 10.3389/fphar.2021.566470 33762932 PMC7982788

135. Wu J. Chen H. Qin J. Chen N. Lu S. Jin J. Li Y. Baicalin Improves Cardiac Outcome and Survival by Suppressing Drp1-Mediated Mitochondrial Fission after Cardiac Arrest-Induced Myocardial Damage Oxidative Med. Cell. Longev. 2021 2021 1 14 10.1155/2021/8865762 PMC7870315 33603953

136. Bondy S.C. The neurotoxicity of environmental aluminum is still an issue NeuroToxicology 2010 31 575 581 10.1016/j.neuro.2010.05.009 20553758 PMC2946821

137. Prakash A. Shur B. Kumar A. Naringin protects memory impairment and mitochondrial oxidative damage against aluminum-induced neurotoxicity in rats Int. J. Neurosci. 2013 123 636 645 10.3109/00207454.2013.785542 23510099

138. Wilkins H.M. Swerdlow R.H. Amyloid precursor protein processing and bioenergetics Brain Res. Bull. 2017 133 71 79 10.1016/j.brainresbull.2016.08.009 27545490 PMC5316384

139. Sabogal-Guáqueta A.M. Manco J.I.M. Ramírez-Pineda J.R. Lamprea-Rodriguez M. Osorio E. Cardona-Gómez G.P. The flavonoid quercetin ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice Neuropharmacol. 2015 93 134 145 10.1016/j.neuropharm.2015.01.027 25666032 PMC4387064

140. A Godoy J. Lindsay C.B. Quintanilla R.A. Carvajal F.J. Cerpa W. Inestrosa N.C. Quercetin Exerts Differential Neuroprotective Effects Against H2O2 and Aβ Aggregates in Hippocampal Neurons: the Role of Mitochondria Mol. Neurobiol. 2017 54 7116 7128 10.1007/s12035-016-0203-x 27796749

141. Markham A. Bains R. Franklin P. Spedding M. Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: How important is BDNF? Br. J. Pharmacol. 2014 171 2206 2229 10.1111/bph.12531 24720259 PMC3976631

142. Arnould T. Vankoningsloo S. Renard P. Houbion A. Ninane N. Demazy C. Remacle J. Raes M. CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation EMBO J. 2002 21 53 63 10.1093/emboj/21.1.53 11782425 PMC125809

143. Ay M. Luo J. Langley M. Jin H. Anantharam V. Kanthasamy A. Kanthasamy A.G. Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson’s Disease J. Neurochem. 2017 141 766 782 10.1111/jnc.14033 28376279 PMC5643047

144. Kim E. Park M. Jeong J. Kim H. Lee S.K. Lee E. Oh B.H. Namkoong K. Cholinesterase Inhibitor Donepezil Increases Mitochondrial Biogenesis through AMP-Activated Protein Kinase in the Hippocampus Neuropsychobiology 2016 73 81 91 10.1159/000441522 27002982

145. Pavlov P.F. Wiehager B. Sakai J. Frykman S. Behbahani H. Winblad B. Ankarcrona M. Mitochondrial γ-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein FASEB J. 2011 25 78 88 10.1096/fj.10-157230 20833873

146. Zhang S. Zhu Q. Chen J.-Y. OuYang D. Lu J.-H. The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer’s disease animal model: A systematic review Phytomedicine 2020 79 153316 10.1016/j.phymed.2020.153316 32942205

147. Alberdi E. Gomez M.V.S. Ruiz A. Cavaliere F. Ortiz-Sanz C. Quintela T. Capetillo-Zarate E. Solé-Domènech S. Matute C. Mangiferin and Morin Attenuate Oxidative Stress, Mitochondrial Dysfunction, and Neurocytotoxicity, Induced by Amyloid Beta Oligomers Oxidative Med. Cell. Longev. 2018 2018 1 13 10.1155/2018/2856063 PMC6022276 30013719

148. Wang W.-W. Han R. He H.-J. Li J. Chen S.-Y. Gu Y. Xie C. Administration of quercetin improves mitochondria quality control and protects the neurons in 6-OHDA-lesioned Parkinson’s disease models Aging 2021 13 11738 11751 10.18632/aging.202868 33878030 PMC8109056

149. Wang Y.-H. Xuan Z.-H. Tian S. He G.-R. Du G.-H. Myricitrin attenuates 6-hydroxydopamine-induced mitochondrial damage and apoptosis in PC12 cells via inhibition of mitochondrial oxidation J. Funct. Foods 2013 5 337 345 10.1016/j.jff.2012.11.004

150. Cai Z. Zeng W. Tao K. Lu F. Gao G. Yang Q. Myricitrin alleviates MPP+-induced mitochondrial dysfunction in a DJ-1-dependent manner in SN4741 cells Biochem. Biophys. Res. Commun. 2015 458 227 233 10.1016/j.bbrc.2015.01.060 25623535

151. Tamilselvam K. Braidy N. Manivasagam T. Essa M.M. Prasad R. Karthikeyan S. Thenmozhi A.J. Selvaraju S. Guillemin G.J. Neuroprotective Effects of Hesperidin, a Plant Flavanone, on Rotenone-Induced Oxidative Stress and Apoptosis in a Cellular Model for Parkinson’s Disease Oxidative Med. Cell. Longev. 2013 2013 1 11 10.1155/2013/102741 24205431 PMC3800605

152. Jiang H. Fang J. Xing J. Wang L. Wang Q. Wang Y. Li Z. Liu R. Tilianin mediates neuroprotection against ischemic injury by attenuating CaMKII-dependent mitochondrion-mediated apoptosis and MAPK/NF-κB signaling Life Sci. 2018 216 233 245 10.1016/j.lfs.2018.11.035 30472297

153. Chen S. Sun M. Zhao X. Yang Z. Liu W. Cao J. Qiao Y. Luo X. Wen A. Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis Mol. Med. Rep. 2019 19 3009 3020 10.3892/mmr.2019.9959 30816517 PMC6423596

154. Huang P. Wu S.-P. Wang N. Seto S. Chang D. Hydroxysafflor yellow A alleviates cerebral ischemia reperfusion injury by suppressing apoptosis via mitochondrial permeability transition pore Phytomedicine 2021 85 153532 10.1016/j.phymed.2021.153532 33735723

155. Amarsanaa K. Kim H.-J. Ko E.-A. Jo J. Jung J.J.A.S.-C. Nobiletin Exhibits Neuroprotective Effects against Mitochondrial Complex I Inhibition via Regulating Apoptotic Signaling Exp. Neurobiol. 2021 30 73 86 10.5607/en20051 33424017 PMC7926044

156. Senyilmaz D. Teleman A.A. Chicken or the egg: Warburg effect and mitochondrial dysfunction F1000Prime Rep. 2015 7 41 10.12703/P7-41 26097714 PMC4447048

157. Samec M. Liskova A. Koklesova L. Samuel S.M. Zhai K. Buhrmann C. Varghese E. Abotaleb M. Qaradakhi T. Zulli A. Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism EPMA J. 2020 11 377 398 10.1007/s13167-020-00217-y 32843908 PMC7429635

158. Hurley D.M. Williams E.R. Cross J.M. Riedinger B.R. Meyer R.A. Abela G.S. Slade J.M. Aerobic Exercise Improves Microvascular Function in Older Adults Med. Sci. Sports Exerc. 2019 51 773 781 10.1249/MSS.0000000000001854 30489496 PMC8480317

159. Quail D.F. Dannenberg A.J. The obese adipose tissue microenvironment in cancer development and progression Nat. Rev. Endocrinol. 2019 15 139 154 10.1038/s41574-018-0126-x 30459447 PMC6374176

160. Yang T. Qiao Y. Xiang S. Li W. Gan Y. Chen Y. Work stress and the risk of cancer: A meta-analysis of observational studies Int. J. Cancer 2019 144 2390 2400 10.1002/ijc.31955 30484859

161. Kunin A. Polivka J. Moiseeva N. Golubnitschaja O. “Dry mouth” and “Flammer” syndromes—neglected risks in adolescents and new concepts by predictive, preventive and personalised approach EPMA J. 2018 9 307 317 10.1007/s13167-018-0145-7 30174766 PMC6107455

162. Tidwell T.R. Søreide K. Hagland H.R. Aging, Metabolism, and Cancer Development: from Peto’s Paradox to the Warburg Effect Aging Dis. 2017 8 662 676 10.14336/AD.2017.0713 28966808 PMC5614328

163. Murata M. Inflammation and cancer Environ. Heal. Prev. Med. 2018 23 1 8 10.1186/s12199-018-0740-1 30340457 PMC6195709

164. Perrino M. Cooke-Barber J. Dasgupta R. Geller J.I. Genetic predisposition to cancer: Surveillance and intervention Semin. Pediatr. Surg. 2019 28 150858 10.1016/j.sempedsurg.2019.150858 31931963

165. Winnard P.T. Pathak A.P. Dhara S. Cho S.Y. Raman V. Pomper M.G. Molecular Imaging of Metastatic Potential J. Nucl. Med. 2008 49 96S 112S 10.2967/jnumed.107.045948 18523068 PMC5516907

166. Golubnitschaja O. Flammer J. Individualised patient profile: clinical utility of Flammer syndrome phenotype and general lessons for predictive, preventive and personalised medicine EPMA J. 2018 9 15 20 10.1007/s13167-018-0127-9 29515684 PMC5833886

167. Grech G. Zhan X. Yoo B.C. Bubnov R. Hagan S. Danesi R. Vittadini G. Desiderio D.M. EPMA position paper in cancer: current overview and future perspectives EPMA J. 2015 6 1 31 10.1186/s13167-015-0030-6 25908947 PMC4407842

168. Li N. Zhan X. Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics EPMA J. 2019 10 153 172 10.1007/s13167-019-00170-5 31258820 PMC6562010

169. Li N. Li H. Wang Y. Cao L. Zhan X. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine EPMA J. 2020 11 661 694 10.1007/s13167-020-00224-z 33240452 PMC7680500

170. Chan Y.-H. Lau K.-K. Yiu K.-H. Li S.-W. Chan H.-T. Fong D. Tam S. Lau C.-P. Tse H.-F. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke Eur. Hear. J. 2008 29 2800 2807 10.1093/eurheartj/ehn409 18812325

171. Grosso G. Micek A. Godos J. Pajak A. Sciacca S. Galvano F. Giovannucci E.L. Dietary Flavonoid and Lignan Intake and Mortality in Prospective Cohort Studies: Systematic Review and Dose-Response Meta-Analysis Am. J. Epidemiol. 2017 185 1304 1316 10.1093/aje/kww207 28472215

172. Peters U. Poole C. Arab L. Does Tea Affect Cardiovascular Disease? A Meta-Analysis Am. J. Epidemiol. 2001 154 495 503 10.1093/aje/154.6.495 11549554

173. Björkenheim A. Szabó B. Áron J. Sztaniszláv Hereditary transthyretin amyloidosis caused by the rare Phe33Leu mutation BMJ Case Rep. 2020 13 e232756 10.1136/bcr-2019-232756 31932463 PMC7021114

174. Kristen A.V. Lehrke S. Buss S. Mereles D. Steen H. Ehlermann P. Hardt S. Giannitsis E. Schreiner R. Haberkorn U. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report Clin. Res. Cardiol. 2012 101 805 813 10.1007/s00392-012-0463-z 22584381 PMC3445797

175. Stone N. Robinson J.G. Lichtenstein A.H. Merz C.N.B. Blum C.B. Eckel R.H. Goldberg A.C. Gordon D. Levy D. Lloyd-Jones D. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Circulation 2014 129 S1 S45 10.1161/01.cir.0000437738.63853.7a 24222016

176. Oliveira P.J. Carvalho R.A. Portincasa P. Bonfrate L. Sardao V.A. Fatty Acid Oxidation and Cardiovascular Risk during Menopause: A Mitochondrial Connection? J. Lipids 2012 2012 1 12 10.1155/2012/365798 22496981 PMC3306973

177. Sathyapalan T. Aye M. Rigby A. Thatcher N. Dargham S. Kilpatrick E. Atkin S. Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause Nutr. Metab. Cardiovasc. Dis. 2018 28 691 697 10.1016/j.numecd.2018.03.007 29739677

178. Cardinali D.P. Vigo D.E. Melatonin, mitochondria, and the metabolic syndrome Cell. Mol. Life Sci. 2017 74 3941 3954 10.1007/s00018-017-2611-0 28819865 PMC11107716

179. Basu A. Du M. Leyva M.J. Sanchez K. Betts N.M. Wu M. Aston C.E. Lyons T.J. Blueberries Decrease Cardiovascular Risk Factors in Obese Men and Women with Metabolic Syndrome J. Nutr. 2010 140 1582 1587 10.3945/jn.110.124701 20660279 PMC2924596

180. Basu A. Betts N.M. Ortiz J. Simmons B. Wu M. Lyons T.J. Low-energy cranberry juice decreases lipid oxidation and increases plasma antioxidant capacity in women with metabolic syndrome Nutr. Res. 2011 31 190 196 10.1016/j.nutres.2011.02.003 21481712 PMC3075541

181. Cassidy A. Bertoia M. Chiuve S. Flint A. Forman J. Rimm E.B. Habitual intake of anthocyanins and flavanones and risk of cardiovascular disease in men Am. J. Clin. Nutr. 2016 104 587 594 10.3945/ajcn.116.133132 27488237 PMC4997299

182. Naruszewicz M. Łaniewska I. Millo B. Dłużniewski M. Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infraction (MI) Atherosclerosis 2007 194 e179 e184 10.1016/j.atherosclerosis.2006.12.032 17320090

183. Lin K.-J. Chen S.-D. Liou C.-W. Chuang Y.-C. Lin H.-Y. Lin T.-K. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson’s Disease Int. J. Mol. Sci. 2019 20 5312 10.3390/ijms20215312 31731450 PMC6862467

184. Dhouafli Z. Cuanalo-Contreras K. Hayouni E.A. Mays C.E. Soto C. Moreno-Gonzalez I. Inhibition of protein misfolding and aggregation by natural phenolic compounds Cell. Mol. Life Sci. 2018 75 3521 3538 10.1007/s00018-018-2872-2 30030591 PMC11105286

185. Levin J. The PROMESA study group Maaß S. Schuberth M. Giese A. Oertel W.H. Poewe W. Trenkwalder C. Wenning G.K. Mansmann U. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): A randomised, double-blind, placebo-controlled trial Lancet Neurol. 2019 18 724 735 10.1016/S1474-4422(19)30141-3 31278067

186. Ostrakhovitch E. Tabibzadeh S. Homocysteine and age-associated disorders Ageing Res. Rev. 2019 49 144 164 10.1016/j.arr.2018.10.010 30391754

187. Morillas-Ruiz J. Rubio-Perez J.M. Albaladejo M. Zafrilla P. Parra S. Vidal-Guevara M. Effect of an antioxidant drink on homocysteine levels in Alzheimer’s patients J. Neurol. Sci. 2010 299 175 178 10.1016/j.jns.2010.08.050 20850133

188. Le Bars P.L. Kieser M. Itil K.Z. A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761® in Dementia Dement. Geriatr. Cogn. Disord. 2000 11 230 237 10.1159/000017242 10867450

189. Levin J. Maaß S. Schuberth M. Respondek G. Paul F. Mansmann U. Oertel W.H. Lorenzl S. Krismer F. The PROMESA study group The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach J. Neural Transm. 2016 123 439 445 10.1007/s00702-016-1507-8 26809243

190. Borsche M. Pereira S.L. Klein C. Grünewald A. Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects J. Park. Dis. 2021 11 45 60 10.3233/JPD-201981 PMC7990451 33074190

191. Francula-Zaninovic S. Nola S.F.Z.A.I.A. Management of Measurable Variable Cardiovascular Disease’ Risk Factors Curr. Cardiol. Rev. 2018 14 153 163 10.2174/1573403X14666180222102312 29473518 PMC6131408

192. Laconi E. Marongiu F. DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes Br. J. Cancer 2020 122 943 952 10.1038/s41416-019-0721-1 32042067 PMC7109142

193. Evans M.A. Sano S. Walsh K. Cardiovascular Disease, Aging, and Clonal Hematopoiesis Annu. Rev. Pathol. Mech. Dis. 2020 15 419 438 10.1146/annurev-pathmechdis-012419-032544 PMC7104598 31689371

194. Hou Y. Dan X. Babbar M. Wei Y. Hasselbalch S.G. Croteau D.L. Bohr V.A. Ageing as a risk factor for neurodegenerative disease Nat. Rev. Neurol. 2019 15 565 581 10.1038/s41582-019-0244-7 31501588

195. Fraga C.G. Croft K.D. Kennedy D. Tomás-Barberán F.A. The effects of polyphenols and other bioactives on human health Food Funct. 2019 10 514 528 10.1039/C8FO01997E 30746536

196. Fusi F. Trezza A. Tramaglino M. Sgaragli G. Saponara S. Spiga O. The beneficial health effects of flavonoids on the cardiovascular system: Focus on K+ channels Pharmacol. Res. 2020 152 104625 10.1016/j.phrs.2019.104625 31918018

197. Maher P. The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases Int. J. Mol. Sci. 2019 20 3056 10.3390/ijms20123056 PMC6627573 31234550

198. Ashrafizadeh M. Ahmadi Z. Mohammadinejad R. Afshar E.G. Tangeretin: a mechanistic review of its pharmacological and therapeutic effects J. Basic Clin. Physiol. Pharmacol. 2020 31 10.1515/jbcpp-2019-0191 32329752

199. Koklesova L. Liskova A. Samec M. Qaradakhi T. Zulli A. Smejkal K. Kajo K. Jakubikova J. Behzadi P. Pec M. Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine EPMA J. 2020 11 261 287 10.1007/s13167-020-00210-5 32547652 PMC7272522

200. Sabel B.A. Wang J. Fähse S. Cárdenas-Morales L. Antal A. Personality and stress influence vision restoration and recovery in glaucoma and optic neuropathy following alternating current stimulation: implications for personalized neuromodulation and rehabilitation EPMA J. 2020 11 177 196 10.1007/s13167-020-00204-3 32547650 PMC7272530

201. Polivka J. Pesta M. Rohan V. Celedova L. Mahajani S. Topolcan O. Golubnitschaja O. Risks associated with the stroke predisposition at young age: facts and hypotheses in light of individualized predictive and preventive approach EPMA J. 2019 10 81 99 10.1007/s13167-019-00162-5 30984317 PMC6459458